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72 Abstract 
73 OBJECTIVES: To characterize the association between type 2 diabetes mellitus (T2DM) subtypes (new-
74 onset-NODM or long-standing-LSDM) and pancreatic cancer (PC) risk, to explore the direction of causation 
75 through Mendelian randomization (MR) analysis, and to assess the mediation role of BMI.
76 DESIGN: Information about T2DM and related factors was collected from 2,018 PC cases and 1,540 controls 
77 from the PanGenEU study. A subset of PC cases and controls had glycated haemoglobin (Hb1Ac), C-
78 Peptide, and genotype data. Multivariate logistic regression models were applied to derive odds ratios (ORs) 
79 and 95% confidence intervals (CIs). T2DM and PC-related SNPs were used as instrumental variables (IV) 
80 in bidirectional MR analysis to test for two-way causal associations between PC, NODM, and LSDM. Indirect 
81 and direct effects of the BMI-T2DM-PC association were further explored using multivariable and mediation 
82 analysis.
83 RESULTS: T2DM was associated with an increased PC risk when compared to non-T2DM (OR=2.50, 
84 95%CI: 2.05-3.05), the risk being greater for NODM (OR=6.39, 95%CI: 4.18–9.78) and among insulin users 
85 (OR=3.69, 95%CI: 2.80-4.86). The causal association between T2DM (57-SNP IV) and PC was not 
86 statistically significant. On the contrary, there was a strong causal association between PC (40-SNP IV) and 
87 NODM (OR=2.85, 95%CI: 2.04-3.98), although genetic pleiotropy was present. Potential mediating effects 
88 of T2DM and obesity (125 SNPs as IV) on both associations were evidenced.
89 CONCLUSION: Findings of this study do not support a causal effect of LSDM on PC, but suggest that PC 
90 is the cause of NODM. The interplay between obesity and T2DM is complex.
91
92 Keywords: Pancreatic cancer risk; Diabetes mellitus type 2; Obesity; Case-control; Causal inference; 
93 Mendelian randomization analysis.
94
95
96
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97 SUMMARY BOX
98 1. What is already known about this subject?
99  The association between type 2 diabetes mellitus (T2DM) and risk of pancreatic cancer (PC) has 
100 been evidenced in numerous studies. 
101  Few studies have suggested the distinct role of T2DM subtypes, new-onset T2DM (NODM) and 
102 long-standing (LSDM), in PC aetiology; while both were associated with PC risk, they may exhibit 
103 a different causal relationship with PC.
104  Uncertainties surrounding the association between T2DM and PC risk also concern confounding 
105 or mediation by obesity, T2DM medication effects, and the causal pathway linking both diseases.
106
107 2. What are the new findings?
108  This study underlines the importance of a timely and accurate T2DM diagnosis in relation to PC 
109 cancer risk; it confirms the time-dependent association between T2DM and PC risk, and sheds 
110 new light on some of the existing knowledge gaps about the causal relationship between the two.
111  Causal inference methods revealed different types of association: a non-existent causal link 
112 between LSDM and PC risk and an effect of PC on NODM, suggesting a reverse causal sequence, 
113 and possibly influenced by weight loss preceding PC.
114  The interplay of obesity in the association between LSDM and PC risk is crucial according to causal 
115 pathways connecting the diseases, with LSDM likely being an intermediate step in the obesity and 
116 PC risk association. 
117
118 3. How might it impact on clinical practice in the foreseeable future?
119  Differences in PC risk by T2DM subtypes and mediating effects by obesity point to a complex 
120 multi-pathway mechanism underlying pancreatic carcinogenesis. These mechanisms need to be 
121 fully explored to pursue PC prevention efforts in the population.
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122  Preventing obesity and related risk factors yield to valuable prevention interventions to reduce the 
123 burden of PC associated with LSDM.
124  Recently diagnosed T2DM patients, i.e., NODM, can be a target group for routine PC screening 
125 and surveillance if early signs of PC disease (i.e., weight loss) is present.
126
127
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128 Introduction
129 Pancreatic cancer (PC) has a high case-fatality rate in Western countries,[1]  expected to rise in coming 
130 years if no immediate actions are taken.[2,3] Many unknowns in PC aetiology remain even regarding some 
131 of the well-established risk factors of this disease.[4] This also applies to type 2 diabetes mellitus (T2DM), 
132 despite representing an important hallmark for PC prevention given the relatively high PC incidence among 
133 T2DM patients.[5] One possible explanation is that observational epidemiological studies are prone to 
134 confounding and reverse causality bias, which makes inference about causal factors of PC impossible. 
135 Mendelian randomization (MR) overcomes this problem by using genetic variants as instrumental variable 
136 (IV) of the risk factor to estimate its causal effect on the outcome.[6,7] 
137 Thus, while a large number of observational studies evidenced that T2DM increases PC risk,[8–10] the 
138 actual role of T2MD in pancreas carcinogenesis remains unsolved. These earlier studies have shown that 
139 the excess risk increases within the first years since the diagnosis of T2DM, decreasing thereafter and 
140 keeping the association with PC risk in the long-term.[9,11] Given this temporal relationship, it is believed 
141 that new-onset and long-standing T2DM (NODM and LSDM, respectively) could play a different role in PC 
142 aetiology.[8] In the former case, the tumour in the pancreas might induce T2DM development through tissue 
143 destruction or paracrine mechanisms. This form of diabetes has been described as pancreatogenic or type 
144 3c.[12] The fact that up to 60-85% of newly diagnosed PC patients present T2DM or hyperglycemia,[12,13] 
145 and that T2DM frequently abates after tumour resection,[14] supports that this mechanism underpins PC-
146 related T2DM. In the case of LSDM, however, chronic hyperinsulinemia could trigger PC development.[15] 
147 Experimental studies support this hypothesis.[16,17] 
148 Common risk factors such as obesity could explain the association between LSDM and PC risk, but this has 
149 not yet been fully explored. Similarly, a common genetic susceptibility between both diseases also needs to 
150 be established.[18] Use of antidiabetic medication is another relevant aspect in the association between 
151 T2DM and PC risk. Insulin-users, relative to non-users, have a higher PC risk,[11] whereas PC risk lowers 
152 among metformin-users.[11,19] It remains to be determined whether this association differs between NODM 
153 and LSDM.
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154 While a MR study on the association between T2DM and PC has been published, it only partially addressed 
155 the questions posed above.[20] Even though this study supported that T2DM and PC are not causally linked, 
156 it did not assess such a relation according to T2DM subgroups.[20] Interestingly, obesity was found to be a 
157 causal factor of PC in this study, but whether obesity interacts with T2DM or mediates the association 
158 between T2DM and PC risk was also not accounted for.[20] Therefore, whether NODM or LSDM, or both, 
159 promote the development of PC, with or without the interplay of obesity, continues to be uncertain. In fact, 
160 there have been few attempts to characterize both T2DM subtypes in PC pathogenesis given the likely 
161 under-ascertainment of NODM at PC diagnosis.[13] Studies reliably profiling characteristics of both T2DM 
162 subtypes are still missing.
163 The aim of this study was to explore the association between LSDM and NODM and PC risk, based on self-
164 reported data and biomarker measures. To disentangle the causal link behind these associations, we 
165 explored through MR the unbiased effect of T2DM-related genetic variants as IV on PC risk and, vice versa, 
166 the effect of PC-related genetic variants as IV on T2DM risk. Potential mediating and modifying effects 
167 between T2DM and BMI on the associations were also explored.
168
169 Methods
170 Study Population: PanGenEU study information is provided in Supplementary Methods and in previous 
171 publications.[21] This study was conducted with ethical approvals of all the participating centres and the 
172 subject´s written consent to participate.
173 Data collection: Information about study protocols to collect data on PC risk factors is provided in 
174 Supplementary Methods. Nearly all PC cases and controls provided biological samples, among them blood, 
175 at enrolment.
176 Assessment of diabetes status: Participants who responded affirmatively to the question “has a doctor ever 
177 told you to have diabetes or elevated glucose levels” were regarded as having diabetes. They were asked 
178 further about the age at which they were first informed they had diabetes and about the use of antidiabetic 
179 medication: oral medication, insulin, or no-medication but diet. This information was used to derive variables 
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180 on diabetes status by time since diagnosis of T2DM (≤2 years, and >2 years since diagnosis to distinguish 
181 between NODM and LSDM, respectively), age at diagnosis (<55, 55-65, and ≥65 years) and by use of 
182 medication (use of oral medication, insulin, diet). T2DM biomarkers, glycated haemoglobin (Hb1Ac) and C-
183 peptide, were determined in 509 PC cases and 413 controls with available non-fasting erythrocyte and 
184 serum samples as described in Supplementary Methods. These data allowed to refine the assessment of 
185 diabetes status. 
186 SNP selection and genotyping: Details on the genotyping of the DNA samples in the PanGenEU study are 
187 provided in Supplementary Methods. A GWAS database review in the GWAS catalog [22] was performed 
188 to identify SNPs associated with T2DM in at least two independent GWAS studies and with a p-value of 
189 ≤5x10-5. SNPs with a minor allele frequency (MAF) ≥0.05 in our study population were selected. In addition, 
190 SNPs of previous T2DM-PC association studies were also included.[23–25] A total of 57 T2DM-related 
191 SNPs were considered. Using the same approach, we selected 40 PC-related SNPs and 125 obesity-related 
192 SNPs for the analyses (Supplementary Table 1).
193 Statistical analysis for the observational association study: There were 2,018 PC cases and 1,540 controls 
194 available for assessing the observational association between T2DM and PC risk (Supplementary Figure 
195 1A). Missing data were imputed as described in Supplementary Methods, whereby a high imputation yield 
196 was reached (Supplementary Table 2). Multivariate unconditional logistic regression was applied to evaluate 
197 the association between T2DM and PC risk by Odds Ratios (ORs) and 95% Confidence Intervals (CI). 
198 Models were adjusted for age, sex and country (Model 1), and subsequently for smoking and body mass 
199 index (BMI) 2 years before recruitment (Model 2). Effect modification was evaluated by adding interaction 
200 terms in the models and comparing them with models lacking this interaction via the likelihood ratio test 
201 (LRT). Effect measure modification was further evaluated in stratified analyses by strata of these variables. 
202 Dose-response and trend analysis was conducted by fitting a T2DM ordinal score in the logistic models. The 
203 dose-response curve was evaluated by applying restricted cubic splines.[26] Interaction by centre but not 
204 by country was apparent; therefore, random centre effects in mixed models when appropriate were 
205 applied.[27] Further details are provided in  Supplementary Methods.
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206 Mediation analysis: As outlined in Supplementary Methods, the counterfactual mediation model for binary 
207 mediators and outcomes was used to explore mediation by estimating the natural indirect and direct effect 
208 of the associations (NIE and NDE, respectively).[28] We explored whether obesity leading to T2DM, and 
209 subsequently to PC, could explain the observational association between T2DM and PC. Similarly, potential 
210 mediating effects of body fat measures on the association between T2DM and PC risk were explored.
211 Mendelian Randomisation Analysis (MR): The causal effect of T2DM subtypes on PC (Supplementary 
212 Figure 1 B) was estimated using several MR tests (Wald ratio, 2-stage least squares -TSLS, inverse 
213 variance weighted method-IVW, and simple median),[29,30] adjusting estimates for potential confounders. 
214 Supplementary Methods detail how the genetic IV for T2DM was built. In addition, the weighted median 
215 estimation and the MR-Egger approach were applied to detect and correct bias due to pleiotropy.[29,31,32] 
216 Bidirectional MR: The same procedure was used to explore the causal effect of PC on T2DM 
217 (Supplementary Figure 1 C). We kept 33 PC-related SNPs for the analyses after removing SNPs in LD and 
218 those associated with other traits (Supplementary Tables 1 and 3). The association of the IV with PC was 
219 estimated in non-T2DM individuals, followed by its association with T2DM in all subjects.
220 MR using pleiotropic genetic variants: Causal assessment of obesity (at two time points: age 50 and 2 years 
221 before the interview) and PC was explored considering an IV of 85 obesity-related SNPs (41 SNPs were 
222 removed due to LD and pleiotropy: Supplementary Tables 1 and 3). Multivariable MR was used to 
223 disentangle further the causal effect of T2DM and obesity on PC using T2DM-SNPs as IV, or PC-SNPs as 
224 IV in the opposite direction (Supplementary Figure 1 D and E). The IVW, TSLS, and Egger methods were 
225 applied in these analyses.[33,34] To extend the aforementioned mediation analyses, potential mediating 
226 effects of obesity or T2DM (mediators) were explored considering separate IVs for the exposure and 
227 mediator variables (Supplementary Figure 1 F and G).[35] NIE and NDE were likewise estimated using the 
228 counterfactual method.[28] 
229 Sensitivity analyses regarding imputation and other issues are detailed in Supplementary Methods. For 
230 instance, we evaluated pleiotropy and unmeasured confounding using several approaches,[31,36,37,38] 
231 Results are presented as OR and 95% CI, considering p-values <0.05 as statistically significant. Statistical 
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232 analyses were conducted using software R-project (version 3.3.0).[39] Mediation models were fitted with the 
233 paramed module in Stata version 14.[40]
234
235 Results
236 Baseline characteristics of cases and controls are displayed in Supplementary Table 4. Cases and controls 
237 with genetic or biomarker data had similar baseline characteristics (data not shown). By T2DM subtypes, 
238 subjects with LSDM were diagnosed with T2DM at younger ages, and were more frequent users of 
239 antidiabetic oral medication than subjects with NODM (Supplementary Table 5).
240 Observational association study: The association between T2DM and PC risk is shown in Table 1. T2DM 
241 (vs non-T2DM) was associated with a 2.5-fold higher risk of PC (95%CI:2.05;3.05). PC risk was higher for 
242 NODM (OR=6.39; 95%CI:4.18;9.78) and notably lower for LSDM (OR=1.86; 95%CI:1.49;2.32). A significant 
243 positive trend of the association by time since diagnosis and age at T2DM diagnosis was observed (p-
244 trend=6.3E-07). The PC risk nonlinear curve of time since T2DM showed a peak at two years following a 
245 gradual decrease of the risk (Supplementary Figure 2). Statistical significance persisted until nearly 30 years 
246 since T2DM diagnosis. Regarding T2DM control measure, the insulin use or non-use of oral medication, 
247 were both significantly associated with a higher PC risk among diabetic patients (OR=3.69 and 2.94, 
248 respectively) compared to non-T2DM. Adjustment for insulin use led to an attenuation of the risk estimates 
249 compared to that observed for age, sex and country-adjusted models (Supplementary Table 6). When 
250 adjusting for time since T2DM diagnosis, intriguingly, risk estimates turned non-significant, except for NODM 
251 (OR=2.64; 95%CI:1.40;4.97) and diabetic patients using insulin (OR=1.61; 95%CI:1.01;2.58). Family history 
252 (FH) of T2DM (vs no FH) was also associated with a significantly increased PC risk (OR=1.22; 
253 95%CI:1.03;1.48).
254 When T2DM status was established upon self-reported and Hb1Ac data (Table 2), the prevalence of T2DM 
255 increased by 15% among PC cases at the expenses of NODM (from 13% to 26%). Accordingly, the PC risk 
256 estimates when considering reclassified T2DM subtypes with biomarker data  were OR=4.63 and 1.97 for 
257 NODM and LSDM, respectively (Supplementary Table 7). Assessment of T2DM status based on both data 
258 was associated with a 3-fold (95%CI:2.21;4.07) higher PC risk, with this risk being mainly driven by 
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259 uncontrolled and undiagnosed T2DM (OR=3.58; 95%CI:2.53;5.11). Increasing levels of Hb1Ac were also 
260 associated with increased PC risk (per 1-unit increase OR=1.49; 95%CI:1.30;1.70 and ≥6.5 vs <5.5 Hb1Ac 
261 levels OR=3.99; 95%CI:2.64;6.01, p-trend=2E-16), whereas C-Peptide levels were inversely associated 
262 with PC risk. Indeed, a remarkable PC risk (OR=8.38; 95%CI:4.71;16.11) was seen for Type 3c-like diabetes 
263 (vs non-T2DM) when both markers were considered.
264 Several factors appeared to modify the association between T2DM and PC risk (Table 3). PC risk was 
265 considerably higher in diabetic patients with a higher educational degree than in those with lower education 
266 attainment (p-het by education=0.004), for either T2DM subtype and irrespective of the type of control 
267 measure used. There was evidence for effect modification by smoking status, with former smokers with 
268 T2DM exhibiting the highest PC risk (p-het by smoking=0.03). By gender, there was a significantly increased 
269 PC risk in males with FH of T2DM, though not in females (p-het by gender=0.007). Estimates were similar 
270 across obese and non-obese subjects. Obesity was not associated with PC risk, except in subgroups of 
271 men (p-het by gender=0.03) (data not shown). There was no indication of effect modification by selected 
272 covariates on the association between Hb1Ac and C-Peptide levels and PC risk (data not shown). 
273 By T2DM subtypes, there were differences in risk estimates across the strata of gender, smoking status, 
274 educational level and post-50s weight-loss compared to non-T2DM (Table 4). For NODM, PC risk appeared 
275 to be higher in men (OR=10.42) than in women (OR=3.73; p-het by gender=0.02); in former smokers 
276 (OR=11.51) than in never (OR=6.21), or current smokers (OR=3.09; p-het by smoking=0.04); and among 
277 those who lost weight (OR=13.06) compared to those who did not (OR=4.76, p-het by weight loss=0.04). 
278 By contrast, in LSDM, a slightly increased PC risk was seen with higher (OR=2.88) vs lower educational 
279 level (OR=1.49; p-het by educational level=0.006). While an interaction could not be established for other 
280 diabetes-related variables, risk of PC tended to be higher in NODM treated with insulin or if oral medication 
281 was not taken. This trend was less apparent for LSDM. Also, there was a borderline significant interaction 
282 effect with BMI in LSDM (Supplementary Table 8). The significance of some of these associations were lost 
283 (e.g., weight loss and gender) when the biomarker data were used to reclassify NODM (data not shown). A 
284 closer evaluation of the association between T2DM subtypes with PC risk revealed that certain subgroups 
285 with NODM (males, insulin users or non-users of oral medication) were more likely to develop PC, whereas 
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286 for LSDM this risk pattern differed (e.g., FH of PC, former alcohol drinkers, and insulin users were at higher 
287 PC risk) (Supplementary Table 9). There were no significant gender, smoking, body fat measures, or 
288 treatment differences between type-3 like NODM, NODM, and LSDM (data not shown).
289 Mendelian Randomization Analyses: Estimates for the causal association between T2DM and PC risk are 
290 shown in Figure 1 and Supplementary Table 10. The genetic score (IV) for T2DM was significantly 
291 associated with both NODM (p-value=1.7E-04) and LSDM (p-value=1.2E-05). However, the causal 
292 association between the IV and PC was not statistically significant for any T2DM subtypes and this finding 
293 was consistent when causal estimates were obtained with the MR-Egger regression. In the opposite 
294 direction, the PC genetic IV score was associated with PC (p-value=9.3E-09) as well as with NODM (p-
295 value=2E-04), though not with LSDM (p-value=0.121). This resulted in a statistically significant causal 
296 association between PC and NODM (ORTSLS=2.52; 95%CI:2.18;2.88). However, pleiotropy was present in 
297 MR-Egger (Intercept=0.09, p-value=0.03) and weighted median regression; these methods did not reach 
298 the level of statistical significance. Similar results were observed for the association between PC and Type 
299 3c (ORTSLS=2.29, p-value=0.02) (data not shown). In multivariable MR, using the T2DM-IV to assess causal 
300 effects on PC risk, comparable results were observed (Supplementary Table 11). Conversely, estimates 
301 were largely affected in the opposite direction, suggesting that PC has causal effects on T2DM risk 
302 independent of the potential pleiotropic effects of obesity (ORTSLS =1.58; 95%CI:1.15;2.17), though still not 
303 supported by MR-Egger regression. Thus, obesity was likely to drive the observed pleiotropy, despite a 
304 causal association with PC risk not being observed (Supplementary Table 12).
305 Mediation analyses results are shown in Figure 2 and Supplementary Table 13. There was an indication for 
306 mediation by overweight/obesity 2 years before recruitment in the T2DM and PC risk association for both 
307 NODM and LSDM though in opposite directions. The association between NODM and PC risk was mediated 
308 by recent weight loss (NIE=0.55), whereas indirect effects by overweight/obesity were less noticeable in the 
309 LSDM-PC risk association. When exploring mediator effects of T2DM, a significant association between 
310 several obesity measures and either NODM or LSDM was seen, but the total effect did not reach the 
311 statistical significance except for overweight/obesity at age 50. Interestingly, NODM was not an intermediate 
312 step in the association between overweight/obesity at age 50 and PC risk, whereas LSDM seemed to be a 
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313 potential mediator in this association (NIE=1.04). These causal pathways were confirmed when 
314 implementing the use of IVs.
315 Sensitivity analyses: The overall results were not altered in sensitivity analyses (Supplementary Tables 14 
316 and 15). Asymmetry in the funnel plots confirmed the presence of pleiotropy in the PC-NODM association 
317 (Supplementary Table 16; Figure 3), but unmeasured confounding was unlikely (Supplementary Table 17).
318
319 Discussion
320 In this large and standardized case-control study, T2DM was associated with an increased PC risk, with 
321 NODM being associated with a higher risk than LSDM. About 34% of PC patients presented with 
322 diabetogenic levels of Hb1Ac (>6.5%) at diagnosis, which entails a 3.3-fold increase in PC risk in comparison 
323 with normal blood levels. The proportion of undiagnosed T2DM in PC patients was notable (15%), showing 
324 the importance of assessing T2DM status with biomarkers at PC diagnosis. This study also showed that PC 
325 risk gradually increased from pre-diabetes range levels. A causal association between LSDM and PC risk 
326 was not observed in MR, whereas estimates derived from bidirectional analyses suggested a causal effect 
327 of PC on NODM risk, though affected by potential pleiotropy. A complex biological interplay between obesity 
328 and LSDM or NODM in PC aetiology was confirmed in mediation analyses. 
329 Pre-existing studies based the assessment of T2DM on self-reports, which is prone to misclassification bias 
330 given that under-diagnosis of T2DM is likely. In case-control studies on PC, this bias is aggravated in view 
331 of the fact that around 30% of PC patients can present undiagnosed T2DM at diagnosis.[41] Moreover, pre-
332 diabetes Hb1Ac levels can represent an important warning sign of subclinical PC, as evidenced in risk 
333 prediction models of PC for diabetic patients.[42] In our study, we used information on Hb1Ac and C-Peptide 
334 levels to reclassify T2DM status and to explore PC risk from pre-diabetes range levels. By doing so, we 
335 assessed more appropriately PC risk associated with T2DM status and Hb1Ac and C-Peptide levels. Only 
336 one previous study within the European Prospective Investigation into Cancer and Nutrition cohort (466 PC 
337 cases and matched controls) assessed PC risk by Hb1Ac levels.[43] Like us, this study also found that pre-
338 diabetes was associated with an increased PC risk. Chari et al., also showed that elevated T2DM biomarker 
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339 levels (e.g., fasting glucose) 2-3 months prior to PC diagnosis were associated with a higher PC risk in a 
340 cohort of 848 PC patients.[44] 
341 Our findings on the observational association between T2DM and PC risk are concordant with previous 
342 studies. Various meta-analyses have shown that T2DM is associated with an approximately two-fold 
343 increased risk of PC (summary RRs ranged from 1.82 to 1.94).[8,10] Also consistent with previous studies, 
344 e.g., the Pancreatic Cancer Case Control Consortium (PanC4) including 8,305 cases and 13,987 controls, 
345 PC risk differs upon timing of T2DM diagnosis, with T2DM lasting less than 2 years (NODM) posing a greater 
346 PC risk than LSDM.[45] Cohort studies using incident T2DM data also support that NODM and LSDM are 
347 two distinct entities in PC aetiology.[9,46,47] As reported within the PanC4 study, our study also evidenced 
348 differing PC risks in men and women with NODM, with men being at a greater PC risk.[45] However, in our 
349 study, this difference turned non-significant when considering reclassified NODM using biomarker data, 
350 probably because of lack of statistical power. By type of medication used to control T2DM, we also observed 
351 that among diabetic patients, non-use of oral antidiabetic agents or use of insulin conferred a higher PC 
352 risk.[45] Nonetheless, our study provides a more thorough assessment of PC risk by T2DM subtypes and 
353 reveals remarkable differences between them. For instance, NODM remained positively associated with PC 
354 risk irrespective of time since T2DM diagnosis (within a 2-year period) and was related to a more frequent 
355 use of insulin. This type of T2DM, if type 3c diabetes, has been previously associated with an earlier insulin 
356 treatment initiation due to a faster or more aggressive disease progression by inducing beta-cell dysfunction 
357 and insulin resistance, as well as by impairing proinsulin processing.[14,48]
358 A genetic link between T2DM and PC risk has been explored in three case-control studies, without finding 
359 any significantly associated T2DM-related variant with PC risk.[18,23,49] The causal link between both 
360 diseases has been previously investigated using MR.[20] Our findings on the absence of a causal 
361 association between T2DM and PC risk are in agreement with this study. In contrast, and as a new finding, 
362 in our study we performed a bidirectional MR in both T2DM subtypes and established their causal 
363 association with PC risk. This approach enabled a more appropriate dissection of the directional association 
364 between T2DM and PC. Thereby, we have elucidated that LSDM is not causally linked to PC, whereas PC 
365 may cause NODM, if the influencing effects of body weight are ruled out. However, our study does not 
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366 support the causal or observational association between BMI and PC risk, possibly due to reverse causation, 
367 a common bias in case-control studies, survival-selection bias, or misclassification of obesity.[50,51] Indeed, 
368 obesity measures were self-reported by the participants at recruitment. Adipose tissue loss in the early 
369 development of PC may explain this lack of association and support reverse causation.[52] In fact, the 
370 presence of coexisting PC and NODM has been related to weight loss prior to PC diagnosis.[53] This is also 
371 supported by a recent study in mouse models showing that adipose wasting is related to altered exocrine 
372 function in early PC.[54] In mediation analyses we could confirm that there is a ‘cross-talk’ between obesity 
373 and T2DM in relation to PC risk. Our findings suggest that weight loss related to NODM are related to the 
374 development of PC, whereas LSDM may mediate the association between obesity and PC risk. 
375 Among the limitations of our study there is pleiotropic effects, i.e. genetic confounding, in the association 
376 study between PC and NODM, despite we accounted for potential pleiotropic associations in multivariable 
377 MR.[33] Thus, pleotropic effects may still have an influence effect on this association. Also, our study may 
378 be prone to confounding bias, although the likelihood of unmeasured confounder effects was low according 
379 to Evalue estimates. We used one-sample data rather than summarized data due to lack of information on 
380 summary statistics for NODM and LSDM in public GWAS databases. Therefore, when MR approaches for 
381 summarized data were applied, we accounted for the correlation between the variants associated with the 
382 exposure and the outcome. In addition, we provided causal estimates using the T2LS method, which is more 
383 convenient for one-sample MR.[32] We considered bidirectional MRA, but this approach also assumes that 
384 the causal association occurs in one direction, such that the impact of feedback loops between the exposure 
385 and outcome cannot be addressed.[29] Our study only included subjects with European ancestry, which 
386 may limit generalizability to other racial/ethnic groups.
387 The strengths of our study include a relatively large sample size, inclusion of a large number of standardized 
388 T2DM-related variables, accounting for biomarker data on Hb1Ac and C-Peptide levels to establish T2DM 
389 status, and the use of MR approaches to assess causal effects between T2DM and PC in both potential 
390 causal directions. We considered two T2DM subtypes and explored their role in PC aetiology, which was 
391 not done before. However, NODM definition was time-based (from self-reports) and misclassification is 
392 likely. Indeed, whether all NODM comprise type 3c diabetes cannot be established due to lack of dynamic 
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393 biomarkers.40 However, using C-Peptide data we could better define this subtype and conduct a more proper 
394 assessment of PC risk. In addition, there might be other T2DM subtypes involved in this disease. Indeed, 
395 one study using medical claims data have identified relevant T2DM subtypes,[55] with possibly different 
396 effect measures in PC disease.
397 In conclusion, while this study confirms the association between T2DM and PC risk, it does not support a 
398 causal effect of T2DM on PC development. Our findings suggest that T2DM is likely to be either a 
399 consequence of an adverse milieu created during the progressive growth of pancreatic cancer cells in the 
400 case of NODM, or a mediator in the causal pathway between obesity and PC in the case of LSDM, rather 
401 than a cause of PC. This study also highlights the importance of diabetogenic levels of Hb1Ac not only for 
402 a proper classification of T2DM status in PC, but also as a predictor of PC risk. These findings, if confirmed 
403 in future studies, may have implications to achieve a breakthrough towards PC prevention. 
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547 Tables
548 Table 1: Association between diabetes-related variables and PC risk in the PanGenEU study (2,018 cases 
549 and 1,540 controls).
550 Table 2: Association between diabetes status based on biomarker levels and PC risk in the Spanish 
551 PanGenEU biomarker study (509 cases and 413 controls).
552 Table 3: Association between diabetes-related variables and PC risk by gender, educational level, obesity 
553 and smoking status in the PanGenEU study (2,018 cases and 1,540 controls).
554 Table 4: Association between diabetes and PC risk according to T2DM subtypes among different subgroups 
555 in the PanGenEU study (2,018 cases and 1,540 controls).
556
557 Figures
558 Figure 1: Forest plot of estimated results (OR and 95%CI) from the observational study and Mendelian 
559 randomisation (MR) analysis, conducted among 1,162 cases and 752 controls with epidemiological and 
560 genetic data. 
561 The point estimates are represented by a bullet along with the 95% confidence intervals. LSDM and NODM 
562 were evaluated in comparison to T2DM-free individuals (1,489 subjects: 851 PC cases and 638 controls), 
563 with subjects classified as either NODM (N=136) or LSDM (N=289) being removed, respectively. All 
564 estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, BMI (<25, 25-30, ≥30 kg/m2), 
565 smoking (never-smokers and tertiles of pack-years), country and the first five principal components for 
566 population ancestries. A and B refer to the directional association between T2DM a d PC risk. The allele 
567 score (IV) included 35 T2DM-SNPs. Mr-Egger Intercept: 0.006 (p-value=0.964) and -0.022 (p-value=0.468), 
568 for NODM and LSDM, respectively. C and D refer to the directional association between PC and T2DM risk. 
569 The allele score (IV) included 33 PC-SNPs. Mr-Egger Intercept: 0.090 (p-value=0.027) and 0.07 (p-
570 value=0.807), for NODM and LSDM, respectively.
571
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572 Figure 2: Directed acyclic graphs showing results of causal mediation analyses evaluating mediator effects 
573 of obesity or T2DM on the PC risk associations by T2DM subtypes. Results are shown for overweight/obesity 
574 assessed 2 years before recruitment for NODM or at age 50 for LSDM. The natural indirect (NIE), direct 
575 (NDE) and total effect (TE) of the associations are shown with corresponding ORs [95% CIs]. Estimates are 
576 derived from counterfactual models (2,018 cases and 1,540 controls) and IV mediation analyses (1,162 
577 cases and 752 controls with epidemiological and genetic data). A and B for LSDM or obesity (mediators) in 
578 association analyses between obesity or NODM and PC risk, respectively. C and D for LSDM or 
579 overweight/obesity (mediators) in association analyses between overweight/obesity or NODM and PC risk, 
580 respectively. 
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581  Table 1: Association between diabetes-related variables and PC risk in the PanGenEU study (2,018 cases 
582 and 1,540 controls).
  Cases Controls      
N=2,018 N=1,540  Model 1              Model 2
  N % N % p-value1 OR [95%CI] OR [95%CI]
Diabetes status: <0.001
    no diabetes 1480 73.30 1342 87.10 Ref. Ref.
    yes 538 26.70 198 12.90 2.56 [2.10;3.11]         2.50 [2.05;3.05]
Family history of diabetes2 <0.001
no diabetes 1210 65.58 879 72.32 Ref. Ref.
yes 635 34.42 371 29.68 1.25 [1.05;1.49] 1.22 [1.03;1.48]
Diabetes by age at diagnosis (years)3 <0.001
no diabetes 1480 73.30 1342 87.10 Ref. Ref.
≤ 55 y 162 8.03 82 5.32 1.56 [1.15;2.11] 1.5 [1.11;2.04]
55 to ≤ 65 y 173 8.57 57 3.70 2.68 [1.92;3.73] 2.59 [1.85;3.63]
> 65 y 203 10.10 59 3.83 4.06 [2.94;5.60] 4.06 [2.93;5.62]
p-trend 2E-16 2E-16
Diabetes by time since diagnosis (years)3 <0.001
   no diabetes 1480 73.30 1342 87.10 Ref. Ref.
   ≤1 y 159 7.88 12 0.78 11.14 [6.09;20.37] 11.28 [6.16;20.68]
   1 to ≤2 y 41 2.03 15 0.97 2.64 [1.40;4.97] 2.47 [1.31;4.66]
   2 to ≤5 y 72 3.57 32 2.08 2.40 [1.54;3.73] 2.35 [1.50;3.68]
   5 to ≤10 y 125 6.19 41 2.66 2.67 [1.81;3.93] 2.60 [1.76;3.84]
   10 to ≤20 y 89 4.41 53 3.44 1.59 [1.09;2.32] 1.57 [1.07;2.30]
   >20 y 52 2.58 45 2.92 1.19 [0.76;1.85] 1.16 [0.74;1.81]
p-trend 9.6E-08 6.3E-07
Diabetes status by subtype <0.001
no diabetes 1480 73.30 1342 87.10 Ref. Ref.
yes, ≤ 2 years (NODM) 200 9.91 27 1.75 6.49 [4.25;9.90] 6.39 [4.18;9.78]
yes, > 2 years (LSDM) 338 16.70 171 11.10 1.90 [1.53;2.37] 1.86 [1.49;2.32]
Diabetes control measures
Diet <0.001
no diabetes 1480 73.30 1342 87.10 Ref. Ref.
yes 420 20.80 149 9.68 2.60 [2.09;3.24] 2.53 [2.03;3.16]
no use 118 5.85 49 3.18 2.43 [1.69;3.49] 2.40 [1.67;3.46]
Use of oral medication <0.001
no diabetes 1480 73.30 1342 87.10 Ref. Ref.
yes 398 19.70 148 9.61 2.41 [1.93;3.00] 2.35 [1.88;2.95]
no use 140 6.94 50 3.25 3.01 [2.13;4.26] 2.94 [2.07;4.17]
Use of insulin <0.001
no diabetes 1480 73.30 1342 87.10 Ref. Ref.
yes 343 17.00 79 5.13 3.76 [2.85;4.95] 3.69 [2.80;4.86]
no use 195 9.66 119 7.73 1.77 [1.37;2.29] 1.72 [1.33;2.23]
583 1 Differences between groups evaluated by the Chi-square test.
584 2 Information on family history of diabetes was not collected in Ireland; results are based on data for 1,845 cases and 1,250 
585 controls.
586 3 Linear association for age since T2DM diagnosis and nonlinear association for time since T2DM (Supplementary Figure 1)
587 Model 1: adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country.
588 Model 2: Model 1 also adjusted for pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-30, ≥30 kg/m2).
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589 Table 2: Association between diabetes status based on biomarker levels and PC risk in the Spanish PanGenEU biomarker study 
590 (509 cases and 413 controls).
Cases
 
 Controls       
N=509 N=413   Model 1    Model2
 P50 IQR P50 IQR p-
value1
OR [95%CI] OR [95%CI]
HbA1c (%)2 per 1 unit increase 6.1 5.6;6.9 5.6 5.4;6.0 <0.001 1.50 [1.31;1.71] 1.49 [1.30;1.70]
C-Peptide (μg/L)2 per log2 
increase
2.3 1.4;3.7 4.2 2.5;6.4 <0.001 0.46 [0.39;0.54] 0.46 [0.39;0.53]
N % N %
Diabetogenic status by HbA1c 
levels
<0.001
HbA1c <6.5% 336 66.00 354 85.70 Ref. Ref.
HbA1c ≥6.5% 173 34.00 59 14.30 3.29 [2.34;4.62] 3.27 [2.32;4.60]
Biomarker and self-reported diabetes status <0.001
no diabetes 286 56.20 322 78.00 Ref. Ref.
self-reported but normal Hb1Ac 
(<6.5%)
50 9.80 32 7.70 1.90 [1.18;3.10] 1.92 [1.19;3.13]
self-reported and HbA1c ≥6.5% 173 34.00 59 14.30 3.59 [2.55;5.11] 3.58 [2.53;5.11]
Reclassified diabetes status <0.001
no diabetes 286 56.20 322 78.00 Ref. Ref.
self-reported and/or HbA1c 
≥6.5%
223 43.80 91 22.00 2.99 [2.21;4.06] 2.99 [2.21;4.07]
Reclassified diabetes status by 
subtype3
no diabetes 286 56.20 322 78.00 Ref. Ref.
NODM 130 25.50 34 8.20 4.63 [3.08;7.12] 4.63 [3.07;7.15]
LSDM 93 18.30 57 13.80 1.98 [1.35;2.90] 1.97 [1.35;2.90]
Biomarker Hb1Ac levels <0.001
<5.5% 100 19.60 129 31.20 Ref. Ref.
5.5-5.8% 72 14.10 121 29.30 0.71 [0.47;1.06] 0.71 [0.47;1.06]
5.8-6.0% 50 9.90 51 12.50 1.26 [0.78;2.04] 1.23 [0.76;1.99]
6.0-6.5% 114 22.40 53 13.00 2.75 [1.80;4.24] 2.72 [1.77;4.17]
 ≥6.5% 173 34.00 59 14.00  4.03 [2.69;6.08] 3.99 [2.64;6.01]
p-trend                         2E-16 2E-16
Reclassified NODM into type 3c-like 
diabetes4
<0.001
no diabetes 286 56.20 322 77.97 Ref. Ref.
NODM and C-Peptide >4.2 μg/L 37 7.20 21 5.08 2.30 [1.31;4.13] 2.28 [1.30;4.10]
NODM and C-Peptide <4.2 μg/L 
(T3c)
93 18.30 13 3.15 8.31 [4.69;15.93] 8.38 [4.71;16.11]
LSDM 93 18.30 57 13.80 1.99 [1.36;2.92] 1.98 [1.35;2.92]
1 Differences between groups evaluated by the Chi-square test (categorical variables) and Mann-Whitney test (continuous variables).
2 Linear association for Hb1Ac and non-linear for C-Peptide levels (Supplementary Figure 1).
3 NODM and LSDM was classified with questionnaire and Hb1Ac biomarker data in the biomarker study population. NODM and LSDM 
assessment based on questionnaire data only or with 
4 NODM based on self-reported and Hb1Ac biomarker data was additionally reclassified into NODM and type 3c-like diabetes (T3C) with C-
peptide biomarker data.
Hb1Ac data in PanGenEU-Spain and PanGenEU is shown in Supplementary Table 6.
Model 1: adjusted for age (<55, 55-65, 65-75, ≥75 years), sex and center (Spain) or country.
Model 2: Model 1 also adjusted for pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-30, ≥30 kg/m2).
591  
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592 Table 3: Association between diabetes-related variables and PC risk by gender, educational level, obesity and smoking status in the PanGenEU study (2,018 cases and 1,540 controls).
 Gender1 Educational level Obese1,2 Smoking status1
 Females (N=1,578) Males (N=1,980) <5-9 years (N=1,405) ≥10 years (N=2,153) No (N=2,872) Yes (N=686) Never (N=1,451) Former (N=1,246) Current (N=861)
  OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI]
Diabetes status by subtype      
no diabetes Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
yes, ≤ 2 years (NODM) 3.67 [2.05;6.58] 10.35 [5.44;19.67] 4.22 [2.38;7.49] 9.54 [5.01;18.16] 6.84 [4.14;11.3] 5.12 [2.28;11.49] 6.07 [3.17;11.89] 11.66 [5.21;26.08] 3.08 [1.44;6.61]
yes, > 2 years (LSDM) 1.71 [1.19;2.46] 2.03 [1.54;2.67] 1.39 [1.02;1.89] 2.64 [1.92;3.62] 1.66 [1.29;2.15] 2.36 [1.52;3.67] 1.58 [1.12;2.21] 2.58 [1.80;3.70] 1.49 [0.90;2.45]
p-value for interaction 0.078 0.004 0.310 0.028  
FH of diabetes3      
no Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
yes 0.93 [0.72;1.21] 1.50 [1.19;1.89] 1.22 [0.95;1.58] 1.23 [0.97;1.56] 1.31 [1.08;1.59] 0.95 [0.64;1.39] 1.03 [0.78;1.34] 1.59 [1.19;2.15] 1.19 [0.83;1.70]
p-value for interaction 0.007 0.971 0.263 0.070  
Diabetes by age at diagnosis      
no diabetes Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
≤ 55 y 1.53 [0.88;2.62] 1.53 [1.06;2.21] 1.03 [0.65;1.63] 2.06 [1.37;3.11] 1.35 [0.95;1.92] 1.97 [1.05;3.65] 1.29 [0.75;2.20] 2.23 [1.35;3.67] 1.22 [0.88;1.68]
55 to ≤ 65 y 2.14 [1.24;3.83] 2.99 [1.98;4.50] 1.42 [0.88;2.28] 4.55 [2.80;7.39] 2.47 [1.66;3.69] 2.72 [1.44;5.12] 1.69 [1.00;2.87] 4.01 [2.30;7.01] 2.78 [1.32;5.85]
> 65 y 2.62 [1.69;4.06] 6.57 [4.00;10.81] 3.05 [2.02;4.60] 6.27 [3.62;10.86] 3.93 [2.71;5.71] 4.25 [2.17;8.32] 3.43 [2.20;5.36] 5.11 [3.00;8.70] 4.92 [1.59;15.23]
p-value for interaction 0.073 4.7E-4 0.682 0.115  
Diabetes controlled with diet      
no diabetes Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
yes 2.13 [1.51;2.92] 2.91 [2.18;3.89] 1.86 [1.38;2.55] 3.48 [2.55;4.76] 2.38 [1.85;3.07] 2.87 [1.81;4.52] 2.05 [1.46;2.82] 3.76 [2.62;5.39] 2.00 [1.21;3.3]
no 2.37 [1.24;4.39] 2.52 [1.61;3.94] 1.61 [1.01;2.59] 4.08 [2.27;7.35] 2.27 [1.47;3.49] 2.7 [1.35;5.38] 2.52 [1.43;4.44] 2.85 [1.51;5.39] 1.62 [0.8;3.28]
p-value for interaction 0.419 0.002 0.669 0.054
Diabetes and oral medication      
no diabetes Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
yes 2.14 [1.5;3.01] 2.54 [1.96;3.40] 1.64 [1.23;2.23] 3.51 [2.52;4.88] 2.27 [1.75;2.96] 2.47 [1.6;3.81] 1.72 [1.23;2.42] 3.69 [2.52;5.42] 2.06 [1.25;3.42]
no 2.25 [1.25;3.87] 3.60 [2.31;5.63] 2.31 [1.40;3.80] 3.82 [2.34;6.23] 2.56 [1.74;3.77] 4.7 [2.04;10.82] 4.36 [2.33;8.16] 3.27 [1.93;5.55] 1.51 [0.75;3.05]
p-value for interaction 0.496 0.003 0.354 0.005  
Diabetes and insulin      
no diabetes Ref. Ref.  Ref. Ref.  Ref. Ref.  Ref.  Ref. Ref.  
yes 3.24 [2.05;5.14] 3.95 [2.79;5.60] 2.92 [1.97;4.34] 4.56 [3.1;6.71] 3.42 [2.5;4.67] 4.62 [2.51;8.49] 3.42 [2.24;5.33] 4.66 [3;7.25] 2.64 [1.45;4.81]
no 1.51 [1.01;2.25] 1.99 [1.42;2.78] 1.17 [0.82;1.67] 2.78 [1.89;4.08] 1.58 [1.16;2.15] 1.98 [1.21;3.23] 1.45 [0.98;2.14] 2.64 [1.7;4.09] 1.34 [0.77;2.35]
p-value for interaction 0.723 0.003 0.498 0.094  
593 1 Odds ratios (ORs) adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country, pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-30, ≥30 kg/m2) (Model 2), except: sex in analyses stratified by sex, BMI in 
594 analyses stratified by obesity and pack-years in analyses stratified by smoking status.
595 2 Obesity status defined based on BMI 2 years before recruitment.
596 3 Information on family history (FH) of diabetes was not collected in Ireland; results based on data for 1,845 cases and 1,250 controls.
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597
598 Table 4: Association between diabetes and PC risk according to T2DM subtypes among different subgroups in the PanGenEU study 
599 (2,018 cases and 1,540 controls).
  No diabetes (Ref.) NODM  LSDM  
  Cases;Controls Cases;Controls OR1 [95%CI] Cases;Controls OR1 [95%CI]
Gender
females 691;624 67;16 3.73 [2.13;6.86] 115;65 1.75 [1.22;2.51]
males 789;718 133;11 10.42 [5.74;20.89] 223;106 2.03 [1.54;2.68]
p-value for interaction 0.0213 0.5704
Obese2
<30 kg/m2 1228;1094 154;19 6.91 [4.29;11.74] 244;129 1.76 [1.36;2.27]
≥30 kg/m2 252;248 46;8 5.01 [2.34;12.04] 94;42 2.37 [1.53;3.71]
p-value for interaction 0.5862 0.2048
Smoking status 
never 573;601 67;11 6.21 [3.3;12.79] 120;79 1.58 [1.13;2.23]
former 457;494 87;7 11.51 [5.5;28.17] 139;62 2.55 [1.79;3.67]
current 450;247 46;9 3.09 [1.49;7.04] 79;30 1.52 [0.93;2.53]
p-value for interaction 0.0418 0.0699
Family history diabetes3
no 1063;1009 105;12 6.66 [3.68;13.10] 162;90 1.61 [1.19;2.19]
yes 417;333 95;15 6.07 [3.49;11.26] 176;81 2.12 [1.52;2.96]
p-value for interaction 0.8253 0.1825
Diabetes controlled with diet
yes 0 156;18 7.31 [4.51;12.55] 264;131 1.89 [1.49;2.42]
no 0 44;9 4.61 [2.28;10.32] 74;40 1.89 [1.25;2.88]
p-value for interaction NA NA
Diabetes with oral medication
yes 0 120;19 4.63 [2.83;7.94] 278;129 2.03 [1.59;2.59]
no 0 80;8 10.71 [5.42;24.37] 60;42 1.48 [0.97;2.27]
p-value for interaction NA NA
Diabetes with insulin
yes 0 123;6 16.97 [7.98;43.91] 220;73 2.60 [1.93;3.52]
no 0 77;21 3.45 [2.12;5.85] 118;98 1.36 [1.01;1.83]
p-value for interaction NA NA
Diabetes by age at diagnosis
≤ 55 y 0 32;5 4.47 [1.78;13.65] 128;75 1.39 [1.01;1.91]
55 to ≤ 65 y 0 56;7 6.47 [3.03;16.01] 121;52 2.13 [1.47;3.11]
> 65 y 0 112;15 7.02 [4.11;12.82] 89;44 2.60 [1.76;3.80]
p-value for interaction NA NA
Educational level
<5 y 230;132 39;5 5.54 [2.21;16.87] 74;40 1.49 [0.92;2.44]
6 to 9 y 353;328 55;11 3.82 [1.94;8.11] 78;60 1.35 [0.89;2.04]
10 to 13 y 517;456 61;8 6.9 [3.35;16.14] 120;44 2.56 [1.70;3.90]
≥14 y 380;426 45;3 16.34 [5.75;68.71] 66;27 2.88 [1.76;4.79]
p-value for interaction 0.1533 0.0059
Weight loss since age 50
yes 486;390 65;6 13.06 [6.05;34.11] 121;55 2.23 [1.61;3.11]
no 994;952 135;21 4.76 [2.59;9.37] 217;116 1.67 [1.15;2.45]
p-value for interaction 0.0441 0.2868
1 Odds ratios (ORs) adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country, pack years (never-smokers and tertiles of pack-years) 
and BMI (<25, 25-30, ≥30 kg/m2), except: sex in analyses stratified by sex, BMI in analyses stratified by obesity and pack-years in analyses 
stratified by smoking status. 
2 Obesity status defined based on BMI 2 years before recruitment.  
3 Information on family history (FH) of diabetes was not collected in Ireland; results based on data for 1,845 cases and 1,250 controls.
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Supplementary Annex. PanGenEU centres and investigators
Spanish National Cancer Research Centre (CNIO), Madrid, Spain: Núria Malats1, Francisco X Real1, 
Evangelina López de Maturana, Paulina Gómez-Rubio, Esther Molina-Montes, Lola Alonso, Mirari 
Márquez, Roger Milne, Ana Alfaro, Tania Lobato, Lidia Estudillo.
Verona University, Italy: Rita Lawlor1, Aldo Scarpa, Stefania Beghelli.
National Cancer Registry Ireland, Cork, Ireland: Linda Sharp1, Damian O’Driscoll.
Hospital Madrid-Norte-Sanchinarro, Madrid, Spain: Manuel Hidalgo1, Jesús Rodríguez Pascual.
Hospital Ramon y Cajal, Madrid, Spain: Alfredo Carrato1, Carmen Guillén-Ponce, Mercedes Rodríguez-
Garrote, Federico Longo-Muñoz, Reyes Ferreiro, Vanessa Pachón, M Ángeles Vaz.
Hospital del Mar, Barcelona, Spain: Mar Iglesias1, Cristina Álvarez-Urturi, Xavier Bessa, Felipe Bory, 
Lucas Ilzarbe, Lucía Márquez, Ignasi Poves, Fernando Burdío, Luis Grande,  Javier Gimeno.
Hospital Vall d´Hebron, Barcelona, Spain: Xavier Molero1, Luisa Guarner, Joaquin Balcells.
Technical University of Munich, Germany: Christoph Michalski1, Jörg Kleeff, Bo Kong.
Karolinska Institute, Stockholm, Sweden: Matthias Löhr1, Jiaqui Huang, Weimin Ye, Jingru Yu.
Hospital 12 de Octubre, Madrid, Spain: José Perea1, Pablo Peláez.
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain: Antoni Farré1, Josefina Mora, Marta Martín, 
Vicenç Artigas, Carlos Guarner, Francesc J Sancho, Mar Concepción, Teresa Ramón y Cajal.
The Royal Liverpool University Hospital, UK: William Greenhalf1, Eithne Costello.
Queen’s University Belfast, UK: Michael O’Rorke1, Liam Murray, Marie Cantwell.
Laboratorio de Genética Molecular, Hospital General Universitario de Elche, Spain: Víctor M Barberá1, 
Javier Gallego.
Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain: Adonina Tardón1, Luis 
Barneo.
Hospital Clínico Universitario de Santiago de Compostela, Spain: Enrique Domínguez Muñoz1, Antonio 
Lozano, Maria Luaces.
Hospital Clínico Universitario de Salamanca, Spain: Luís Muñoz-Bellvís1, J.M. Sayagués, M.L. 
Gutíerrrez Troncoso, A. Orfao de Matos.
University of Marburg, Department of Gastroenterology, Phillips University of Marburg, Germany: Thomas 
Gress1, Malte Buchholz, Albrecht Neesse.
Queen Mary University of London, UK: Tatjana Crnogorac-Jurcevic1, Hemant M Kocher, Satyajit 
Bhattacharya, Ajit T Abraham, Darren Ennis, Thomas Dowe, Tomasz Radon
Scientific advisors of the PanGenEU Study: Debra T Silverman (NCI, USA) and Douglas Easton (U. of 
Cambridge, UK)
1 Principal Investigator in each centre
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4
Supplementary Methods
Study population: PanGenEU (the European Study into Digestive Illnesses and Genetics) is a mostly hospital-based case-
control study of PC conducted in six European countries (Spain, Germany, Ireland, United Kingdom, Italy and Sweden) and 
28 centers, designed to evaluate environmental and genetic factors associated with PC. Recruitment of PC cases and 
corresponding controls matched by region, sex and age (± 10 years) took place from 2007 to 2014 in all participating 
centers, except in those from Italy were only cases were ascertained. Inclusion criteria were cases diagnosed or suspected 
of having PC, who had lived in one of the study areas and aged older than 18 years. All medical records were reviewed to 
ensure the PC diagnosis for study entry. Participants incapable of participating in the study due to impairment of physical 
ability were excluded. Response rates varied by center and were on average 76% among cases and 85% among controls. 
Data collection: A standardized epidemiological questionnaire including self-reported socio-demographic and 
anthropometric data (location of body fat, height and weight at different ages: age 20 and 50 years, 2 years before 
recruitment and at PC diagnosis), the likely fat accumulation zone (abdominal, hips, all equally, no extra weight gain), family 
history of cancer including PC, medical history (e.g., chronic pancreatitis, diabetes and others) including regular use of 
specific medication, and lifestyle behaviors (e.g., smoking and alcohol habits) was administered by trained personnel in a 
face-to-face interview. This information was used as input to generate other variables such as body mass index (BMI: weight 
in kg / height in m2: <25, 25-30, ≥30 kg/m2) at different ages (20, 50 and two years before recruitment). Weight gain (> 5 or 
10 kg) between young and old adulthood (20 and 50 years, respectively), and weight loss since age 50 until two years 
before recruitment, was also derived (younger than 50 years, yes weight gain/loss, no weight gain/loss).
T2DM biomarker assays: Non-fasting erythrocyte and serum samples collected at subject recruitment and stored at -80ºC 
from 509 PC cases and 413 controls of the Spanish PanGenEU study were analysed blinded to the disease status. All 
individuals had epidemiological information; 356 cases and 298 controls also participated in the genetic study. Glycated 
haemoglobin or Hb1Ac (as percentage of haemoglobin and mmol/mol) was measured with an automated HPLC analyzer 
(Menarini Diagnostics, Spain) at the Hospital 12 de Octubre, Madrid (Spain). Mean intra-batch and inter-batch coefficients 
of variations were 0.42% and 8.46%, respectively. Diabetes status based on Hb1Ac data was established for values above 
6.5%. Undiagnosed T2DM, most likely NODM, was identified on this basis. Other predefined levels of Hb1Ac were 
considered to distinguish between prediabetes (≥6% and <6.5%) and non-diabetes (<6%). Furthermore, undiagnosed or 
uncontrolled T2DM (Hb1Ac≥6.5%), or HbA1c levels <6.5% but self-reported T2DM diagnosis, i.e., controlled T2DM patients, 
were considered in separate categories. C-peptide was measured at University Hospital Giessen and Marburg using a 
Cobas e411 (Roche Diagnostics, Mannheim, Germany) by means of Electro-chemiluminescence immune assay. 
Coefficients of variations were <5%. Type 3c-like diabetes was defined as NODM with C-peptide levels below the median 
(4.2 μg/L in controls). 
SNP selection and genotyping: Consistent quality SNP data was available for 1,162 cases and 540 controls who provided 
blood samples. DNA samples were genotyped on the Infinium OncoArray-500K at the CEGEN (Spanish National Cancer 
Research Centre, CNIO). The genotype data was filtered for call rate, relatedness, European ancestry <80% and sex 
chromosome abnormalities. Overall, 451,883 SNPs passed these quality filters and underwent imputation of missing 
genotypes using IMPUTE v2. The control group was enlarged with 212 controls participating in two Spanish bladder cancer 
case-control studies (EPICURO and ISBlaC), with analogous characteristics to the source population (Spanish PC cases; 
44% females and mean age=64.7 years) and with genotype and epidemiological data available. Similar protocols for data 
collection and genotyping were used in all studies. Genotype distributions of each SNP and deviation from Hardy-Weinberg 
equilibrium were assessed separately in each of the geographical areas. Principal components to control for population 
stratification were calculated with the prcomp function in R.
Imputation: Missing data (9.8% in the dataset containing 63 variables with predictors to improve the imputation 
performance), assumed to be at random, was substituted by the random forest (RF) imputation algorithm. RF tress (n=100) 
trained on the observed values of the data set predicted the missing values of the data. The out-of-bag error (OOB) was 
considered as a measure of the imputation error. A further test of imputation performance consisted of comparing observed 
imputed values versus the expected values (% of concordance) in a test set resembling the pattern of missingness of the 
original data. Mean OOB error (0.05) and concordance estimates (92.5%) demonstrated good imputation performance 
(Supplementary Table 2).
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5
Statistical analysis for the observational association study: There were 2,018 PC cases and 1,540 controls available for 
assessing the observational association between T2DM and PC risk (Supplementary Figure 1A). Descriptive statistics by 
case-control status were performed, evaluating differences between the groups via Pearson chi-square and Student’s t-test 
or Mann-Whitney test, where appropriate. Multivariate unconditional logistic regression was applied to evaluate the 
association between T2DM and PC risk by Odds Ratios (ORs) and 95% Confidence Intervals (CIs). The influence of 
smoking, obesity (BMI variables), alcohol status, asthma and/or allergies, educational level, and family history of PC, was 
evaluated in age, sex and country-adjusted models (Model 1), whereby only smoking (non-smokers and smokers in tertiles 
of pack-years) proved to be a confounder (>10% change of the risk estimators). The lowest Akaike´s Information Criterion 
value was reached by further including BMI 2 years before recruitment (normal weight/overweight/obese) (Model 2).
Effect modification by country, center, age, gender, smoking and alcohol status, and BMI variables was evaluated by adding 
interaction terms in the models, and comparing them with models lacking this interaction (likelihood ratio test, LHR). Effect 
measure modification was further evaluated in stratified analyses by subgroups of these variables.
Dose-response and trend analysis was conducted by fitting the categorized variables (time since T2DM, age at T2DM 
diagnosis and Hb1Ac levels) as an ordinal score in the logistic models. The dose-response curve was evaluated by applying 
restricted cubic splines (3 knots at the 10%, 50% and 90% percentile).24 Linearity tests were performed by comparing via 
the LHR test the continuous variable models as nonlinear or as linear. Interaction by centre but not by country was apparent; 
therefore, random centre effects in mixed models when appropriate were applied.25 
Mediation analysis: The counterfactual mediation model for binary mediators and outcomes was used to explore mediation 
effects on the associations.26 We explored whether obesity leading to T2DM, and subsequently to PC, could explain the 
observational association between T2DM and PC. With this method, we estimated the total effect (TE) of obesity on PC by 
determining a natural direct effect (NDE) of obesity on PC and a natural indirect effect (NIE) of obesity on T2DM accounting 
by the influence of confounders. Standard errors were generated using Monte Carlo bootstrapping with 1,000 replications. 
Similarly, potential mediating effects of obesity on the association between T2DM and PC risk were explored.
Mendelian Randomization Analysis (MRA): The causal effect of T2DM subtypes on PC (Supplementary Figure 1 B) was 
estimated using several MRA approaches (Wald ratio, 2-stage least squares -TSLS, inverse variance weighted method-
IVW, and simple median),27 adjusting estimates for the aforementioned potential confounders. Some of these methods were 
applied via the MendelianRandomization R package.28 A total of 16 variants in high LD (R2>0.8) were removed for these 
analyses (Supplementary Table 1). Since genetic variants for T2DM can be confounded by BMI effects due to sharing of 
variants (i.e., pleiotropy), we tested for the association between the variants and BMI, as well as other confounders, and 
removed those variants showing an association with other traits (Supplementary Table 3). After removing them, 35 T2DM-
SNPs remained to build the IV. The genetic association of this IV with T2DM was estimated in controls only, and 
subsequently with PC in the case-control setting. Logistic regression models adjusted for age, sex and five principal 
components to control for population stratification were used to assess the per allele effect of each SNP and of the genetic 
score. In addition, the weighted median estimation and the MR-Egger approach were applied to detect and correct bias due 
to pleiotropy.27,29,30 The weighted median estimator reflects the median of the distribution of weighted Wald ratio estimates. 
This test is less sensitive to the influence of pleiotropic variants since less weight is given to outlying estimates.29,30 The MR-
Egger approach performs a weighted linear regression of the genetic associations with the outcome on the genetic 
associations with the exposure, while keeping the intercept unconstrained. This test provides evidence for directional 
pleiotropy when the intercept differs from zero.29 
Bidirectional MRA: The same procedure was used to explore the causal effect of PC on T2DM (Supplementary Figure 1 C). 
We kept 33 PC-related SNPs for the analyses after removing SNPs in LD and those associated with other traits 
(Supplementary Tables 1 and 3). The association of the IV with PC was estimated in non-T2DM, followed by its association 
with T2DM in all subjects.
MRA using pleiotropic genetic variants: Causal assessment of obesity (at age 50 and 2 years before the interview) and PC 
was explored considering 85 obesity-related SNPs (41 SNPs were removed due to LD and associations with other traits: 
Supplementary Tables 1 and 3). Multivariable MRA was used to disentangle further the causal effect of T2DM and obesity 
on PC using T2DM-SNPs as IV (Supplementary Figure 1 D), or PC-SNPs as IV in the opposite direction (Supplementary 
Figure 1 E). The IVW, TSLS and Egger methods were applied in these analyses.31,32  In line with the aforementioned 
mediation analyses, we explored potential mediating effects of obesity or T2DM (mediators) using separate IVs 
(Supplementary Figure 1 F and G).33 Direct and indirect effects were estimated using the counterfactual method.26
Page 35 of 64
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
6
Sensitivity analyses: We compared estimates from the unimputed and imputed data to assess the robustness of the results. 
Although heterogeneity by country was absent, we evaluated the consistency of the results across countries by removing 
each country at a time from the analyses. This was particularly relevant for PC cases from Italy due to the lack of matched 
controls. Sensitivity analyses also comprised the assessment of T2DM status based on questionnaire, i.e. self-reported 
(SR) data, or biomarker data in different study settings. In MRA, to further detect potential pleiotropic variants, we also 
removed SNPs that were outliers based on Cook´s distances and removed additional variants potentially associated with 
other phenotypes.29 The latter were identified in publicly available data from GWAS studies (PhenoScanner database).34 
The MR-base platform was also used to inspect the presence of pleiotropy. For instance, scatter plots of the gene-outcome 
and gene-exposure associations and for the SNP risk increase against the strength of instrumental SNPs were constructed, 
along with leave-one out analyses funnel plots for visual assessment of pleitropy.35 In addition, since unmeasured 
confounding is a major concern of causal inference in observational studies, we tested by estimating the E-Value how strong 
such confounders would have to be related to the exposure and the outcome to explain away the observed association.36 
High E-Values reflect less impact of these confounders on the observed associations. 
Results were comparable to those seen in analyses of the original data, regarding the use of unimputed missing data 
(Supplementary Tables 14), country-specific data (data not shown), reclassified T2DM status with biomarker data (e.g., 
Supplementary Table 15), and in analyses of the influence of pleiotropic effects in MRA (Supplementary Table 16 and 
Supplementary Figure 3). The E-value for the causal effect between NODM or LSDM with PC risk (E-value = 12.29 and 
3.12, respectively) suggested that unmeasured confounders are unlikely to explain away the effect of the observed 
association, especially with regard to NODM (Supplementary Table 17).
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7
Supplemental Table 1: Selected genetic variants of T2DM, PC, and obesity.
T2DM PC Obesity
ID SNP Chr Position SNP Chr Position SNP Chr Position
1 rs2641348 1 120437884 rs13303010 1 894573 rs11208659 1 65979280
2 rs340874 1 214159256 rs1747924 1 64538961 rs3101336 1 72751185
3 rs13414140 2 43671176 rs351365 1 113046395 rs2568958 1 72765116
4 rs243021 2 60584819 rs10919791 1 199965168 rs7531118 1 72837239
5 rs2943641 2 227093745 rs2816938 1 199985368 rs1993709 1 72838529
6 rs780094 2 27741237 rs3790844 1 200007432 rs1514177 1 74991402
7 rs1801282 3 12393125 rs962856 2 67593803 rs1514174 1 74993063
8 rs1470579 3 185529080 rs1486134 2 67639769 rs17381664 1 78048331
9 rs4402960 3 185511687 rs12478462 2 153654720 rs12408810 1 106640943
10 rs11708067 3 123065778 rs9854771 3 189508471 rs17024258 1 110147321
11 rs2877716 3 123094451 rs6537481 4 148396094 rs633715 1 177852580
12 rs4411878 3 64703665 rs2736098 5 1294086 rs12130212 1 209727257
13 rs6802898 3 12391207 rs35226131 5 1295373 rs2605100 1 219644224
14 rs10012946 4 6293350 rs401681 5 1322087 rs6429082 1 235600129
15 rs7708285 5 76425867 rs31490 5 1344458 rs12145833 1 243483754
16 rs9472138 6 43811762 rs17688601 7 40866663 rs6711012 2 624034
17 rs1535500 6 39284050 rs73328514 7 47488569 rs12463617 2 629244
18 rs4712523 6 20657564 rs6971499 7 130680521 rs11127485 2 632028
19 rs10946398 6 20661034 rs2941471 8 76470404 rs10189761 2 646364
20 rs7754840 6 20661250 rs10094872 8 128719884 rs10182181 2 25150296
21 rs7766070 6 20686573 rs1561927 8 129568078 rs17025867 2 40578559
22 rs7756992 6 20679709 rs10991043 9 106797388 rs6726292 2 55156630
23 rs13234407 7 130438214 rs2417487 9 106887581 rs6731302 2 58833493
24 rs1635852 7 28189411 rs687289 9 136137106 rs887912 2 59302877
25 rs2191348 7 15064255 chr9_136149229 9 136149229 rs7581710 2 121195181
26 rs4607517 7 44235668 rs7310409 12 121424861 rs16867321 2 181362379
27 rs13266634 8 118184783 chr12_121454622 12 121454622 rs7603514 2 206836612
28 rs3802177 8 118185025 rs9554197 13 28476978 rs2943650 2 227105921
29 rs896854 8 95960511 rs9581943 13 28493997 rs11680012 2 238672425
30 rs2383208 9 22132076 rs9543325 13 73916628 rs12635698 3 16408489
31 rs10811661 9 22134094 chr16_75263661 16 75263661 rs1435703 3 25560231
32 rs10512085 9 81924713 rs7200646 16 86335351 rs13078807 3 85884150
33 rs7903146 10 114758349 rs4795218 17 36078510 rs7638110 3 138903985
34 rs5015480 10 94465559 rs77038344 17 38644214 rs1516725 3 185824004
35 rs1111875 10 94462882 chr17_70400166 17 70400166 rs9816226 3 185834499
36 rs7901695 10 114754088 rs7214041 17 70401476 rs13130484 4 45175691
37 rs11257655 10 12307894 rs1517037 18 56878274 rs10938397 4 45182527
38 rs11603334 11 72432985 rs6073450 20 43086648 rs4833407 4 113311790
39 rs1552224 11 72433098 rs450960 22 18316304 rs10433903 4 118093137
40 rs5215 11 17408630 rs16986825 22 29300306 rs4864201 4 130731284
41 rs5219 11 17409572 rs925642 4 187678866
42 rs10830963 11 92708710 rs2307111 5 75003678
43 rs2237892 11 2839751 rs2112347 5 75015242
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44 rs1387153 11 92673828 rs374748 5 127699375
45 rs2334499 11 1696849 rs9328321 6 5600438
46 rs231362 11 2691471 rs4712652 6 22078615
47 rs1353362 12 71613276 rs999943 6 33624733
48 rs2612067 12 66170163 rs2274459 6 33762242
49 rs7965349 12 121471931 rs2206277 6 50798526
50 rs1359790 13 80717156 rs987237 6 50803050
51 rs2028299 15 90374257 rs734597 6 50836279
52 rs7172432 15 62396389 rs2207139 6 50845490
53 rs4778582 15 80420966 rs2807278 6 131809920
54 rs8042680 15 91521337 rs10953454 7 104503813
55 rs8050136 16 53816275 rs545854 8 10002570
56 rs9939609 16 53820527 rs17150703 8 9745798
57 rs4430796 17 36098040 rs17126232 8 17977650
58 rs4735692 8 76615663
59 rs10968576 9 28414339
60 rs1412239 9 28425515
61 rs16933812 9 36969205
62 rs2275848 9 95887320
63 rs10508503 10 16299951
64 rs16923476 10 23858211
65 rs7474896 10 37982097
66 rs10999409 10 72332440
67 rs2116830 10 78646536
68 rs11042023 11 8662516
69 rs297325 11 16389594
70 rs4756846 11 16403511
71 rs12295638 11 26605331
72 rs988712 11 27563382
73 rs2030323 11 27728539
74 rs564343 11 65895166
75 rs1048466 12 551550
76 rs3782724 12 6466081
77 rs10875976 12 50226467
78 rs7138803 12 50247468
79 rs11109072 12 97901270
80 rs9568856 13 54064981
81 rs9568867 13 54107352
82 rs17081231 13 66967622
83 rs534870 13 80959207
84 rs7989336 13 97017548
85 rs1957894 14 61908111
86 rs699363 14 72692493
87 rs11624704 14 78786077
88 rs7141420 14 79899454
89 rs2370983 14 79903376
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9
90 rs8028313 15 68043057
91 rs970843 15 98876029
92 rs2531995 16 4013467
93 rs12446554 16 19935073
94 rs12446632 16 19935389
95 rs11639988 16 19944363
96 rs7498665 16 28883241
97 rs7184597 16 28921809
98 rs1421085 16 53800954
99 rs1558902 16 53803574
100 rs1121980 16 53809247
101 rs17817449 16 53813367
102 rs8043757 16 53813450
103 rs8050136 16 53816275
104 rs7185735 16 53822651
105 rs9941349 16 53825488
106 rs9923451 16 78952439
107 rs1424233 16 79682751
108 rs7187365 16 86511915
109 rs9299 17 46669430
110 rs7503807 17 78591111
111 rs1805081 18 21140432
112 rs17697518 18 38765659
113 rs1631486 18 53026357
114 rs17700144 18 57811982
115 rs538656 18 57850422
116 rs17782313 18 57851097
117 rs10871777 18 57851763
118 rs476828 18 57852587
119 rs11152213 18 57852948
120 rs17773430 18 57963117
121 rs1800437 19 46181392
122 rs10423928 19 46182304
123 rs6110577 20 15335754
124 rs13041126 20 51092996
125 rs11088859 21 22689344
126 rs5762430 22 28378472
SNPs in LD (>0.8) for T2DM-related variants: rs4712523, rs10946398, rs7754840, rs7756992, rs9939609, rs8050136, rs5215, rs1552224, rs11603334, 
rs5015480, rs7903146, rs10811661, rs3802177, rs1801282, rs2877716, rs1470579
SNPs in LD (>0.8) for PC-related variants: rs31490, rs9554197
SNPs in LD (>0.8) for Obesity-related variants: rs2568958, rs7531118, rs1514174, rs12463617, rs11127485, rs10189761, rs10938397, rs2112347, 
rs987237, rs734597, rs2207139, rs1412239, rs7184597, rs1558902, rs1121980, rs17817449, rs8043757, rs8050136, rs7185735, rs9941349, 
rs9923451, rs12446554, rs12446632, rs11639988, rs538656, rs17782313, rs10871777, rs476828, rs11152213, rs10423928
Page 39 of 64
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
10
Supplemental Table 2: Evaluation of the performance of the missing data imputation.
Variable
Proportion of 
missings (%)
OOB Error Test1
in test set
Imputed 
values
 in test 
set
Proportion of 
concordance ()
OOB Error Test1
in full set
status 0.00 0.0000 0 NA 0.0000
country 0.00 0.0000 0 NA 0.0000
gender 0.11 0.1315 2 50 0.1320
smoking status 3.29 0.0103 30 96.67 0.0015
alcohol status 1.83 0.4893 21 57.14 0.4117
chronic pancreatitis status 3.71 0.0052 37 100 0.0053
diabetes by type 2.67 0.0031 26 100 0.0003
educational level 2.22 0.6254 21 47.62 0.5677
FH of pancreatic cancer 3.57 0.0576 26 100 0.0498
FH of diabetes2 20.15 0.4210 226 100 0.3537
periodontitis 26.39 0.1903 257 81.71 0.1745
recession 37.16 0.4041 362 67.96 0.2862
diabetes diet control 3.99 0.0031 41 100 0.0000
diabetes oral medication 3.23 0.0021 42 97.62 0.0000
diabetes insulin control 3.65 0.0021 29 100 0.0000
Pancreatitis type 3.71 0.0294 46 93.48 0.0330
asthma status 9.33 0.0215 113 100 0.0015
nasal allergies 8.63 0.0088 94 98.94 0.0018
cancer 8.12 0.1393 86 90.70 0.1367
diabetes status 1.60 0.0000 15 100.00 0.0000
metabolic syndrome 18.27 0.0061 182 97.25 0.0007
center 0.00 0.0000 0 NA 0.0000
weighton body site 8.68 0.0621 96 91.67 0.0160
BMI 2 years before 4.86 0.0000 42 100 0.0000
BMI at age 20 19.93 0.0447 192 95.31 0.0074
BMI at age 50 27.18 0.0351 257 94.55 0.0108
pack-years in tertiles 10.20 0.0055 90 96.67 0.0006
age in categories 0.37 0.0643 2 100 0.0220
place fat deposition 8.68 0.0132 92 97.83 0.0031
weight gain 5 kg 32.66 0.0029 309 95.15 0.0008
weight gain 10 kg 32.66 0.0000 324 94.75 0.0004
weight at age 20 in tertiles 
20t
18.94 0.0109 173 98.27 0.0010
weight at age 50 in tertiles 25.74 0.0202 257 94.55 0.0019
Weight since  age 50 26.45 0.0000 250 98.00 0.0000
hypertension 9.19 0.0044 96 94.79 0.0009
cholesterol 10.85 0.0000 116 98.28 0.0022
height in tertiles 2.22 0.0206 27 100 0.0040
smoking duration in tertiles 9.47 0.0143 90 97.78 0.0053
smoking intensity in tertiles 3.20 0.0145 31 100 0.0044
NA=not applicable
FH=family history
Covariates used to improve imputation were case-control status, country, center, medical history (cancer, asthma, allergies, chronic pancreatitis), 
smoking variables (intensity and duration) and weight and height.
1 Out of bag (OOB) error rates: normalized squared error for continuous variables (e.g. age) and proportion of falsely classified entries for categorical 
variables. Values close to zero indicated good performance and values close to one indicated bad performance.
2 Concordance test applied to the study population without Ireland since this country did not collect information on family history of the disease.
Page 40 of 64
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
11
Supplemental Table 3: Genetic variants associated individually at p-value level <0.05 with T2DM and PC, as 
well as with selected covariates in the study population (752 controls).
T2DM-SNPs
NODM LSDM PC smoking obesity
any rs2943641 
(p=0.018)
rs1801282 
(p=0.051)
rs7901695 
(p=0.045)
rs7903146 
(p=0.016)
rs2191348 
(p=0.015)
rs13266634 
(p=0.006)
rs3802177 
(p=0.005)
rs7965349 
(p=0.011)
rs2641348 
(p=0.006)
rs13234407 
(p=0.011)
rs1111875 
(p=0.018)
rs5015480 
(p=0.020)
rs2334499 
(p=0.043)
rs10830963 
(p=0.044)
rs4430796 
(p=0.031)
PC-SNPs
NODM LSDM PC smoking obesity
rs2816938.199985368.T.A 
(p=0.006)
rs7310409 
(p=0.016)
chr12_121454622_C_T  
(p=0.005)
any rs351365.113046395 
(p=0.002)
rs2816938.199985368 
(p=0.001)
rs1486134.67639769 
(p=0.049)
rs31490
(p=0.029)
rs73328514.47488569 
(p=0.024)
rs6971499
(p=0.007)
rs2941471.76470404 
(p=0.031)
rs9543325 
(p=0.003)
chr16_75263661 
(p=0.001)
chr17_70400166 
(p=0.005)
rs7214041.70401476 
(p=0.005)
rs6537481.148396094 
(p=0.001)
rs1747924.64538961 
(p=0.011)
rs2816938.199985368 
(p=0.012)
rs2736098.1294086 
(p=0.005)
rs17688601.40866663 
(p=0.026)
NA: not applicable
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Supplemental Table 4: General characteristics of the study population. PanGenEU study (2,018 cases and 
1,540 controls). Imputed data.
  Cases Controls    
N=2018 N=1540
  N % N % p-value OR [95%CI]
Country <0.001
Spain 884 43.80 770 50.00
England 126 6.24 22 1.43
Germany 131 6.49 111 7.21
Ireland 173 8.57 290 18.80
Italy 533 26.40 0 0.00
Sweden 171 8.47 347 22.50
Gender 0.143
females 873 43.30 705 45.80 Ref.
males 1145 56.70 835 54.20 1.11 [0.97;1.27]
Age (years) 64.3 12.10 66.8 12.50 <0.001 0.98 [0.98;0.99]
Age in categories <0.001
<55 y 409 20.30 261 16.90 Ref.
55-65 y 500 24.80 323 21.00 0.99 [0.80;1.22]
65-75 y 708 35.10 500 32.50 0.90 [0.74;1.10]
≥75 y 401 19.90 456 29.60 0.56 [0.46;0.69]
BMI 2 years before 0.971
<25 761 37.70 575 37.30 Ref.
25-29.99 868 43.00 668 43.40 0.98 [0.85;1.14]
≥30 389 19.30 297 19.30 0.99 [0.82;1.19]
BMI at age 20 0.263
<25 1750 86.70 1330 86.40 Ref.
25-29.99 228 11.30 189 12.30 0.92 [0.75;1.13]
≥30 40 1.98 21 1.36 1.44 [0.85;2.51]
BMI at age 50 <0.001
<25 620 30.70 612 39.70 Ref.
25-29.99 929 46.10 604 39.20 1.52 [1.30;1.77]
≥30 468 23.20 324 21.00 1.43 [1.19;1.71]
Weight gain >5kg (age 20-50) 0.343
no 391 19.40 319 20.70 Ref.
yes 1627 80.60 1221 79.30 1.09 [0.92;1.28]
Weight gain >10kg (age 20-50) <0.001
no 742 36.80 676 43.90 Ref.
yes 1276 63.20 864 56.10 1.35 [1.18;1.54]
Weight loss since age 50 0.012
no 1346 66.70 1089 70.70 Ref.
yes 672 33.30 451 29.30 1.21 [1.04;1.39]
Smoking status <0.001
never 760 37.70 691 44.90 Ref.
former 683 33.80 563 36.60 1.10 [0.95;1.28]
current 575 28.50 286 18.60 1.83 [1.53;2.18]
Pack-years in tertiles <0.001
never smokers 760 37.70 691 44.90 Ref.
[0.05,12.95] 259 12.80 269 17.50 0.88 [0.72;1.07]
[13,36] 583 28.90 327 21.20 1.62 [1.37;1.92]
[36.3,240] 416 20.60 253 16.40 1.49 [1.24;1.80]
Alcohol status <0.001
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never 599 29.70 390 25.30 Ref.
former 508 25.20 234 15.20 1.41 [1.16;1.73]
current 911 45.10 916 59.50 0.65 [0.55;0.76]
Pancreatitis type <0.001
no 1918 95.00 1523 98.90 Ref.
acute 81 4.01 15 0.97 4.25 [2.51;7.71]
chronic 19 0.94 2 0.13 7.06 [2.03;48.0]
Educational level (years of education) <0.001
<5 y 343 17.00 177 11.50 Ref.
6 to 9 y 486 24.10 399 25.90 0.63 [0.50;0.79]
10 to 13 y 698 34.60 508 33.00 0.71 [0.57;0.88]
≥14 y 491 24.30 456 29.60 0.56 [0.44;0.69]
Family history of PC <0.001
no 1889 93.60 1499 97.30 Ref.
yes 129 6.39 41 2.66 2.49 [1.76;3.60]
Periodontitis 0.643
no 1744 86.40 1340 87.00 Ref.
yes 274 13.60 200 13.00 1.05 [0.87;1.28]
Recession 0.003
no 1481 73.40 1197 77.70 Ref.  
yes 537 26.60 343 22.30 1.27 [1.08;1.48]
Asthma <0.001
no 1887 93.50 1381 89.70 Ref.  
yes 131 6.49 159 10.30 0.60 [0.47;0.77]
Nasal allergies <0.001
no 1771 87.80 1236 80.30 Ref.  
yes 247 12.20 304 19.70 0.57 [0.47;0.68]
Hypertension <0.001
no 1324 65.60 913 59.30 Ref.  
yes 694 34.40 627 40.70 0.76 [0.67;0.88]
Cholesterol <0.001
no 1459 72.30 1000 64.90 Ref.  
yes 559 27.70 540 35.10 0.71 [0.61;0.82]
Differences between cases and controls evaluated via Chi-squared test (categprocal variables) and Student´s t-test or Mann-Whitney (continuous 
variables).
Odds Ratios (OR) derived from unadjusted unconditional logistic resgression models.
Data of all variables was self-reported.
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Supplemental Table 5: Baseline characteristics of NODM and LSDM in the PanGenEU study (538 cases and 
198 controls). Imputed data.
  LSD M NODM   
  N=509  N=227  OR 95%CI
N % N % p-value NODM vs LSDM
Age (years)     <0.001  
 <55 37 7.27 28 12.30 Ref.  
 55-65 92 18.10 67 29.50 1.04 [0.58;1.86]
 65-75 213 41.80 83 36.60 1.94 [1.11;3.37]
 ≥75 167 32.80 49 21.60 2.57 [1.42;4.63]
Gender 0.818
females 180 35.40 83 36.60 Ref.
males 329 64.60 144 63.40 1.05 [0.76;1.46]
Smoking status 0.441
never 199 39.10 78 34.40 Ref.
former 201 39.50 94 41.40 0.84 [0.58;1.20]
current 109 21.40 55 24.20 0.78 [0.51;1.18]
Alcohol status 0.127
never 155 30.50 57 25.10 Ref.
former 140 27.50 78 34.40 0.66 [0.44;1.00]
current 214 42.00 92 40.50 0.86 [0.58;1.26]
Chronic pancreatitis 0.298
no 504 99.00 222 97.80 Ref.
yes 5 0.98 5 2.20 0.44 [0.12;1.65]
Educational level (years) 0.632
<5 y 114 22.40 44 19.40 Ref.
6 to 9 y 138 27.10 66 29.10 0.81 [0.51;1.27]
10 to 13 y 164 32.20 69 30.40 0.92 [0.58;1.43]
≥14 y 93 18.30 48 21.10 0.75 [0.46;1.23]
Family history PC 0.318
no 478 93.90 218 96.00 Ref.
yes 31 6.09 9 3.96 1.55 [0.75;3.54]
Family history Diabetes 0.667
no 252 49.50 117 51.50 Ref.
yes 257 50.50 110 48.50 1.08 [0.79;1.48]
Periodontitis 0.221
no 421 82.70 197 86.80 Ref.
yes 88 17.30 30 13.20 1.37 [0.88;2.17]
Recession 0.667
no 381 74.90 174 76.70 Ref.
yes 128 25.10 53 23.30 1.1 [0.77;1.60]
Diabetes age diagnosis <0.001
         ≤ 55y 207 40.70 37 16.30  Ref.  
                55 to ≤ 65y 167 32.80 63 27.80  0.48 [0.30;0.75]
                      > 65y 135 26.50 127 55.90  0.19 [0.12;0.29]
Diabetes with diet 0.770
yes 395 77.60 174 76.70 Ref.
no 114 22.40 53 23.30 0.95 [0.65;1.38]
Diabetes with oral medication    <0.001  
 yes 407 80.00 139 61.20 Ref.  
 no 102 20.00 88 38.80 0.4 [0.28;0.56]
0.916
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Differences between cases and controls evaluated via Chi-squared test (categprocal variables) and Student´s t-test (continuous variables).
Odds Ratios (OR) derived from unadjusted unconditional logistic resgression models.
Diabetes with insulin
yes 293 57.60 129 56.80 Ref.
no 216 42.40 98 43.20 0.97 [0.71;1.33]
Asthma 0.135
no 467 91.70 216 95.20 Ref.
yes 42 8.25 11 4.85 1.75 [0.91;3.65]
Nasal allergies 0.46
no 453 89.00 197 86.80 Ref.
yes 56 11.00 30 13.20 0.81 [0.51;1.32]
Metabolic syndrome 0.116
Any one 146 28.70 58 25.60 Ref.
Any two 170 33.40 96 42.30 0.7 [0.47;1.04]
Any three 151 29.70 60 26.40 1 [0.65;1.53]
All four 42 8.25 13 5.73 1.27 [0.65;2.64]
BMI 2 years before 0.172
<25 128 25.10 47 20.70 Ref.
25-29.99 245 48.10 126 55.50 0.72 [0.48;1.06]
≥30 136 26.70 54 23.80 0.93 [0.58;1.47]
BMI at age 20 0.713
<25 421 82.70 184 81.10 Ref.
25-29.99 72 14.10 37 16.30 0.85 [0.55;1.32]
≥30 16 3.14 6 2.64 1.15 [0.46;3.29]
BMI at age 50 0.99
<25 110 21.60 48 21.10 Ref.
25-29.99 241 47.30 108 47.60 0.97 [0.64;1.46]
≥30 158 31.00 71 31.30 0.97 [0.62;1.51]
Pack-years in tertiles 0.585
never 
smokers 199 39.10 78 34.40 Ref.
[0.05,12.95] 51 10.00 27 11.90 0.74 [0.43;1.28]
[13,36] 129 25.30 64 28.20 0.79 [0.53;1.18]
[36.3,240] 130 25.50 58 25.60 0.88 [0.59;1.32]
Weightgain >5kg (age 20-50) 0.943
no 58 11.40 27 11.90 Ref.
yes 451 88.60 200 88.10 1.05 [0.64;1.70]
Weightgain >10kg (age 20-50) 0.797
no 155 30.50 72 31.70 Ref.
yes 354 69.50 155 68.30 1.06 [0.75;1.48]
Hypertension 0.596
no 241 47.30 113 49.80 Ref.
yes 268 52.70 114 50.20 1.1 [0.81;1.51]
Cholesterol 0.981
no 316 62.10 140 61.70 Ref.
yes 193 37.90 87 38.30 0.98 [0.71;1.36]
Weight loss since age 50 0.429
no 333 65.4 156 68.7 Ref.
yes 176 34.6 71 31.3 1.16 [0.83;1.63]
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Supplemental Table 6: Association between diabetes-related variables and PC risk in the PanGenEU study 
(2,018 cases and 1,540 controls) when adjusting for T2DM treatment and duration of the disease.
Age, sex, country-
adjusted (Model 1)
Model 1 + use of oral 
medication
Model 1 + use of 
insulin
Model 1 + duration of 
diabetes
OR [95%CI] OR [95%CI] OR [95%CI] OR [95%CI]
Diabetes status:
   no diabetes Ref. Ref. Ref. Ref.
   yes 2.56 [2.10;3.11] 3.01 [2.13;4.26] 1.77 [1.37;2.29] 1.19 [0.76;1.85]
Diabetes status by subtype
   no diabetes Ref. Ref. Ref. Ref.
   yes, ≤ 2 years (NODM) 6.49 [4.25;9.90] 6.36 [3.95;10.26] 4.51 [2.88;7.06] 2.64 [1.4;4.97]
   yes, > 2years (LSDM) 1.90 [1.53;2.37] 1.85 [1.25;2.73] 1.27 [0.96;1.69] 1.19 [0.76;1.85]
Family history of diabetes1
   no diabetes Ref. Ref. Ref. Ref.
   yes 1.25 [1.05;1.49] 1.07 [0.89;1.28] 1.07 [0.89;1.28] 1.07 [0.89;1.28]
Diabetes by age at diagnosis 
(years)2
   no diabetes Ref. Ref. Ref. Ref.
   ≤ 55 y 1.56 [1.15;2.11] 1.83 [1.21;2.76] 0.91 [0.62;1.32] 1.17 [0.75;1.83] 
   55 to ≤ 65 y 2.68 [1.92;3.73] 3.23 [2.02;5.15] 1.81 [1.25;2.61] 1.50 [0.79;2.86]
   > 65 y 4.06 [2.94;5.60] 4.75 [3.13;7.28] 2.79 [1.96;3.97]
p-trend 2E-16 p-trend 1.2E-05 p-trend 6.6E-07 p-trend 0.122
Diabetes by time since 
diagnosis (years)2
   no diabetes Ref. Ref. Ref. Ref.
   ≤1 y 11.14 [6.09;20.37] 11.04 [5.83;20.93] 7.24 [3.89;13.5] NA NA
   1 to ≤2 y 2.64 [1.40;4.97] 2.61 [1.3;5.22] 1.72 [0.89;3.35] NA NA
   2 to ≤5 y 2.40 [1.54;3.73] 2.36 [1.35;4.14] 1.73 [1.09;2.76] NA NA
   5 to ≤10 y 2.67 [1.81;3.93] 2.63 [1.57;4.47] 1.73 [1.14;2.66] NA NA
   10 to ≤20 y 1.59 [1.09;2.32] 1.56 [0.94;2.62] 0.91 [0.58;1.42] NA NA
   >20 y 1.19 [0.76;1.85] 1.17 [0.69;1.98] 0.61 [0.36;1.04] NA NA
p-trend 9.6E-08 p-trend 5.5E-10 p-trend 1.4E-11 p-trend NA
Diabetes controlled with diet
   no diabetes Ref. Ref. Ref. Ref.
   yes 2.60 [2.09;3.24] 3.08 [2.14;4.43] 1.75 [1.32;2.32] 1.22 [0.78;1.92]
   no use 2.43 [1.69;3.49] 2.84 [1.81;4.47] 1.82 [1.24;2.69] 1.04 [0.6;1.82]
Use of oral medication
   no diabetes Ref. Ref. Ref. Ref.
   yes 2.41 [1.93;3.00] NA NA 1.74 [1.33;2.28] 1.19 [0.75;1.9]
   no use 3.01 [2.13;4.26] NA NA 1.89 [1.25;2.85] 1.17 [0.69;1.98]
Use of insulin
   no diabetes Ref. Ref. Ref. Ref.
   yes 3.76 [2.85;4.95] 3.96 [2.71;5.79] NA NA 1.61 [1.01;2.58]
   no use 1.77 [1.37;2.29] 1.89 [1.25;2.85] NA NA 0.61 [0.36;1.04]
1 Information on family history of diabetes was not collected in Ireland; results are based on data for 1,845 cases and 1,250 controls
2 Linear associations for age since T2DM diagnosis and nonlinear association for time since T2DM (Supplemental Figure 1)
Model 1: adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country.
Model 2: Model 1 also adjusted for use of oral medication.
Model 3: Model 1 also adjusted for use of insulin.
Model 4: Model 1 also adjusted for duration of T2DM.
NA=not applicable
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Supplemental Table 7: Association between T2DM status based on Hb1Ac levels and questionnaire data and PC risk in the PanGenEU study.
Cases Controls Crude Model Model1 Model2
  P50 IQR P50 IQR p-value1 OR [95%CI]  OR [95%CI]  OR [95%CI]
HbA1c (%)2,3 per 1 unit increase 6.1 5.6;6.9 5.6 5.4;6.0 <0.001 1.48 [1.30;1.69] 1.50 [1.31;1.71] 1.49 [1.30;1.70]
C-Peptide2,3 per log2 increase 2.3 1.4;3.7 4.2 2.5;6.4 <0.001 0.45 [0.38;0.56] 0.46 [0.39;0.54] 0.46 [0.39;0.53]
N % N %
Diabetogenic status by HbA1c levels3 <0.001
HbA1c <6.5% 336 66 354 85.7 Ref. Ref. Ref.
HbA1c ≥6.5% 173 34 59 14.3 3.08 [2.22;4.32] 3.29 [2.34;4.62] 3.27 [2.32;4.60]
Biomarker and self-reported diabetes status <0.001
no diabetes 286 56.2 322 78 Ref. Ref. Ref.
self-reported but normal Hb1Ac levels 50 9.8 32 7.7 1.76 [1.10;2.84] 1.9 [1.18;3.10] 1.92 [1.19;3.13]
self-reported and HbA1c ≥6.5% 173 34 59 14.3 3.3 [2.37;4.65] 3.59 [2.55;5.11] 3.58 [2.53;5.11]
Diabetes status3 <0.001
no diabetes 350 68.7 341 82.6 Ref. Ref. Ref.
yes 159 31.3 72 17.40 2.15 [1.57;2.96] 2.26 [1.64;3.15] 2.26 [1.64;3.15]
Reclassified diabetes status3 <0.001
no diabetes 286 56.2 322 78 Ref. Ref. Ref.
self-reported and/or HbA1c ≥6.5% 223 43.8 91 22 2.76 [2.07;3.70] 2.99 [2.21;4.06] 2.99 [2.21;4.07]
Diabetes status by subtype3 <0.001
no diabetes 350 68.7 341 82.6 Ref. Ref. Ref.
NODM 66 13 15 3.6 4.29 [2.47;7.93] 4.53 [2.59;8.42] 4.58 [2.61;8.55]
LSDM 93 18.3 57 13.8 1.59 [1.11;2.29] 1.65 [1.14;2.41] 1.64 [1.13;2.40]
Reclassified diabetes status by subtypes3 <0.001
no diabetes 286 56.2 322 78 Ref. Ref. Ref.
NODM 130 25.5 34 8.2 4.3 [2.89;6.57] 4.63 [3.08;7.12] 4.63 [3.07;7.15]
LSDM 93 18.3 57 13.8 1.84 [1.28;2.66] 1.98 [1.35;2.90] 1.97 [1.35;2.90]
Biomarker Hb1Ac levels3 <0.001
<5.5 100 19.6 129 31.2 Ref. Ref. Ref.
5.5-5.8 72 14.1 121 29.3 0.77 [0.52;1.14] 0.71 [0.47;1.06] 0.71 [0.47;1.06]
5.8-6.0 50 9.9 51 12.5 1.26 [0.79;2.03] 1.26 [0.78;2.04] 1.23 [0.76;1.99]
6.0-6.5 114 22.4 53 13 2.76 [1.83;4.22] 2.75 [1.80;4.24] 2.72 [1.77;4.17]
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 ≥6.5 173 34 59 14 3.77 [2.55;5.62]  4.03 [2.69;6.08]  3.99 [2.64;6.01]
      p-trend 2.70E-10  p-trend                        2.00E-16  p-trend                        2.00E-16  
Reclassified NODM into type 3c-like diabetes3
no diabetes 286 56.20 322 77.97 Ref. Ref. Ref.
NODM and C-Peptide >4.2 μg/L 37 7.20 21 5.08 1.98 ]1.15;3.52] 2.30 [1.31;4.13] 2.28 [1.30;4.10]
NODM and C-Peptide <4.2 μg/L (T3c) 93 18.30 13 3.15 8.05 [4.57;15.37] 8.31 [4.69;15.93] 8.38 [4.71;16.11]
LSDM 93 18.30 57 13.80 1.84 [1.28;2.66] 1.99 [1.36;2.92] 1.98 [1.35;2.92]
Diabetes status4 <0.001  
no diabetes 1480 73.3 1342 87.1 Ref. Ref. Ref.
yes 538 26.7 198 12.9 2.46 [2.06;2.95] 2.56 [2.10;3.11] 2.5 [2.05;3.05]
Reclassified diabetes status4 <0.001
no diabetes 1416 70.2 1323 85.9 Ref. Ref. Ref.
self-reported and/or HbA1c ≥6.5% 602 29.8 217 14.1 2.59 [2.18;3.08] 2.85 [2.36;3.45] 2.79 [2.31;3.39]
Diabetes status by subtype PanGenEU4 <0.001
no diabetes 1480 73.3 1342 87.1 Ref. Ref. Ref.
NODM 200 9.91 27 1.75 6.68 [4.52;10.3] 6.49 [4.25;9.90] 6.39 [4.18;9.78]
LSDM 338 16.7 171 11.1 1.79 [1.47;2.19] 1.9 [1.53;2.37] 1.86 [1.49;2.32]
Reclassified diabetes status by subtypes4 <0.001
                      no diabetes 1416 70.2 1323 85.9 Ref. Ref. Ref.
                      NODM 264 13.1 46 3 5.36 [3.93;7.49] 5.74 [4.14;8.11] 5.67 [4.09;8.03]
                      LSDM 338 16.7 171 11.1  1.85 [1.52;2.26]  2.03 [1.62;2.53]  1.98 [1.59;2.48]
Reclassified NODM into type 3c-like diabetes4 <0.001
   no diabetes 1416 70.2 1323 85.9 Ref. Ref. Ref.
   NODM and C-Peptide >4.2 μg/L 171 8.5 33 2.2 4.84 [3.36;7.20] 4.65 [3.16;7.02] 4.51 [3.06;6.83]
   NODM and C-Peptide <4.2 μg/L (T3c) 93 4.6 13 0.8 6.68 [3.86;12.58] 8.83 [5.06;1.67] 8.86 [5.07;1.68]
   LSDM 338 16.7 171 11.1 1.85 [1.52;2.26] 2.06 [1.65;2.56] 2.00 [1.61;2.51]
diabetes status5 <0.001  
no diabetes 596 67.4 628 81.6 Ref. Ref. Ref.
yes 288 32.6 142 18.4 2.14 [1.70;2.70] 2.09 [1.64;2.66] 2.07 [1.62;2.64]
Reclassified diabetes status5 <0.001
no diabetes 532 60.2 609 19.1 Ref. Ref. Ref.
self-reported and/or HbA1c ≥6.5% 352 39.8 161 80.9 2.5 [2.01;3.12] 2.57 [2.04;3.24] 2.54 [2.01;3.22]
Diabetes status by subtype5 <0.001
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no diabetes 596 67.4 628 81.6 Ref. Ref. Ref.
NODM 109 12.2 20 2.6 5.74 [3.60;9.63] 5.7 [3.54;9.62] 5.67 [3.52;9.60]
LSDM 179 20.3 122 15.8 1.55 [1.20;2.00] 1.47 [1.12;1.93] 1.45 [1.11;1.91]
Reclassified diabetes status by subtypes5 <0.001
no diabetes 532 60.2 609 79.1 Ref. Ref. Ref.
NODM 173 19.6 39 5.1 5.08 [3.56;7.42] 5.4 [3.75;7.94] 5.35 [3.71;7.88]
 LSDM 179 20.2 122 15.8  1.68 [1.30;2.18]  1.63 [1.24;2.15]  1.62 [1.23;2.14]
Reclassified NODM into type 3c-like diabetes5
  no diabetes 532 60.2 609 79.1 Ref. Ref. Ref.
  NODM and C-Peptide >4.2 μg/L 80 9.1 26 3.4 3.52 [2.26;5.66] 3.49 [2.21;5.68] 3.41 [2.15;5.57]
  NODM and C-Peptide <4.2 μg/L (T3c) 93 10.5 13 1.7 8.19 [4.70;15.50] 9.46 [5.40;17.96] 9.47 [5.40;18.02]
  LSDM 179 20.2 122 15.8 1.68 [1.30;2.18] 1.65 [1.26;2.18] 1.63 [1.24;2.16] 
1 Differences between groups evaluated by the Chi-square test (categorical variables) and Mann-Whitney test (continuous variables).
2 Linear association for Hb1Ac levels and non-linear for C-Peptide (Supplemental Figure 1).
3 NODM and LSDM was classified with questionnaire and biomarker data in the biomarker study population (509 cases and 413 controls).
4 NODM and LSDM was classified with questionnaire and biomarker data in the entire study population (2,018 cases and 1,540 controls).
5 NODM and LSDM was classified with questionnaire and biomarker data in the PanGenEU-Spain study population (884 cases and 770 controls).
Crude Model: unadjusted.
Model 1: adjusted for age (<55, 55-65, 65-75, ≥75 years), sex and center (Spain) or country.
Model 2: Model 1 also adjusted for pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-30, ≥30 kg/m2).
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Supplemental Table 8: Association between T2DM and PC risk by T2MD subtypes and other covariates in the 
PanGenEU study (2,018 cases and 1,540 controls).
  No diabetes (Ref.) NODM  LSDM  
  Cases;Controls Cases;Controls OR1 [95%CI] Cases;Controls OR1 [95%CI]
Alcohol status
never 451;326 47;10 3.62 [1.81;7.90] 101;54 1.43 [0.95;2.16]
former 329;195 71;7 6.59 [3.09;16.33] 108;32 2.61 [1.66;4.20]
current 700;821 82;10 8.21 [4.30;17.34] 129;85 1.71 [1.24;2.37]
p-value for interaction 0.3530 0.3914
Chronic pancreatitis
no 1469;1342 195;27 6.31  [4.2;9.83] 335;169 1.92 [1.55;2.40]
yes 11;0 5;0 NA 3;2 NA
p-value for interaction NA NA
Family history PC
no 1378;1305 191;27 6.26 [4.16;9.77] 311;167 1.88 [1.50;2.35]
yes 93;37 9;0 NA 27;4 2.79 
[0.90;10.72]
p-value for interaction 0.2209 0.4220
Asthma
no 1378;1207 192;24 6.83 [4.46;10.9] 317;150 2   [1.59; 2.52]
yes 102;135 8;3 2.56 [0.6;13.26] 21;21 1.34 [0.61; 2.9]
p-value for interaction 0.1853 0.1832
Nasal allergies
no 1292;1065 172;25 5.5 [3.59; 8.75] 307;146 1.84 [1.46; 2.34] 
yes 188;277 28;2 17.39 [4.92; 110.72] 31;25 2.1 [1.14; 3.88]
p-value for interaction 0.1131 0.8289
BMI 2 years before
<25 635;524 45;2 20.35 [6.11;126.34] 79;49 1.22 [0.79;1.87]
25-29.99 593;570 109;17 5.41 [3.2;9.65] 165;80 2.16 [1.57;2.99]
≥30 252;248 46;8 5.01 [2.34;12.04] 94;42 2.37 [1.53;3.71]
p-value for interaction 0.1222 0.0496
BMI at age 20
<25 1311;1162 163;21 6.72 [4.26;11.12] 271;147 1.78 [1.40;2.26]
25-29.99 143;161 31;6 5.06 [2.08;14.28] 53;19 3.11 [1.69;5.93] 
≥30 26;19 6;0 NA 11;5 2.69 
[0.63;13.71]
p-value for interaction 0.5767 0.3708
BMI at age 50 
<25 516;562 39;9 4.21 [2.04;9.57] 66;44 1.58 [1.02;2.44]
25-29.99 665;517 100;8 11.03 [5.55;25.21] 164;77 1.93 [1.39;2.70]
≥30 299;263 61;10 4.98 [2.48;10.92] 108;50 2.14 [1.40;3.28]
p-value for interaction 0.1333 0.635
Age categorized:
<55 356;249 24;4 4.73 [1.69;16.79] 29;8 3.17 [1.42;7.78]
55-65 369;295 61;6 7.94 [3.56;21.15] 70;22 2.20 [1.28;3.86]
65-75 482;430 75;8 7.54 [3.72;17.45] 151;62 2.18 [1.54;3.11]
≥75 273;368 40;9 4.74 [2.27;10.89] 88;79 1.34 [0.93;1.94]
p-value for interaction 0.7985 0.2534
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Place fat deposition 
Never carried 
any extra weight
90;72 4;1 4.95 [0.59;111.11] 10;4 2.71 
[0.77;11.19]
Abdominal 966;927 140;20 6.24 [3.87;10.53] 239;134 1.78 [1.38;2.30]
Hips 127;120 10;2 7.52 [1.66;53.69] 12;5 4.94 
[1.55;18.11]
All over equally 297;223 46;4 8.9 [3.43;30.4] 77;28 2.05 [1.24;3.47]
p-value for interaction 0.8896 0.5682
Weight gain >5kg between age 20-50
no 326;299 26;1 19.9 [4.08;359.30] 39;19 1.64 [0.89;3.10] 
yes 1154;1043 174;26 6.12 [4.02;9.67] 299;152 2.04 [1.61;2.59]
p-value for interaction 0.1841 0.4969
Weight gain >10kg between age 20-50
no 578;613 62;10 6.08 [3.17;12.90] 102;53 2.06 [1.42;3.01]
yes 902;729 138;17 6.62 [3.98;11.66] 236;118 1.87 [1.42;2.46]
p-value for interaction 0.8334 0.7456
1 Odds ratios (ORs) adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country, pack years (never-smokers and tertiles of pack-years) 
and BMI (<25, 25-30, ≥30 kg/m2), except: sex in analyses stratified by sex, BMI in analyses stratified by obesity and pack-years in analyses 
stratified by smoking status. 
2 Obesity status defined based on BMI 2 years before recruitment.
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Supplemental Table 9: Factors associated with PC risk among patients with NODM and LSDM in the PanGenEU study 
(2,018 cases and 1,540 controls).
   NODM 
(N=227)
  LSDM 
(N=509)
  NODM SR + BIOM 
(N=310)
  Cases;
Controls
OR1 [95%CI] p-
value
Cases;
Controls
OR1 [95%CI] p-
value
Cases;
Controls
OR1 [95%CI] p-
value
Gender females 67;16 Ref.  115;65 Ref.  103;22 Ref.  
males 133;11 2.59 [1.07;6.32] 0.04 223;106 1.07 [0.7;1.63] 0.75 161;24 1.2 [0.62;2.35] 0.59
Age groups <65y 85;10 Ref.  99;30 Ref.  106;17 Ref.  
≥65y 115;17 3.94 [0.8;19.44] 0.09 239;141 1.33 [0.67;2.67] 0.42 158;29 1.73 [0.54;5.60] 0.36
Pbese2 no 154;19 Ref.  244;129 Ref.  207;32 Ref.  
yes 46;8 0.6 [0.22;1.61] 0.31 94;42 1.22 [0.78;1.93] 0.39 57;14 0.56 [0.27;1.19] 0.13
Smoking status never 67;11 Ref.  120;79 Ref.  96;18 Ref.  
former 87;7 1.03 [0.32;3.32] 0.96 139;62 1.46 [0.88;2.40] 0.14 108;15 0.87 [0.36;2.1] 0.76
current 46;9 0.52 [0.15;1.74] 0.29 79;30 1.25 [0.69;2.28] 0.46 60;14 0.56 [0.22;1.46] 0.24
Alcohol status never 47;10 Ref.  101;54 Ref.  69;16 Ref.  
former 71;7 1.97 [0.59;6.60] 0.27 108;32 1.91 [1.06;3.43] 0.03 91;13 1.64 [0.66;4.06] 0.29
current 82;10 1 [0.29;3.45] 1 129;85 0.76 [0.45;1.3] 0.32 104;17 1.27 [0.51;3.14] 0.61
Family history PC no 191;27 Ref.  311;167 Ref.  252;44 Ref.  
yes 9;0 NA NA 1 27;4 3.98 [1.33;11.93] 0.01 12;2 1.34 [0.27;6.61] 0.72
Family history 
diabetes no 105;12 Ref.  161;90 Ref.  154;26 Ref.  
yes 95;15 1.02 [0.42;2.47] 0.97 176;81 1.34 [0.89;2.02] 0.16 110;20 1.07 [0.54;2.10] 0.84
Periodontitis no 175;22 Ref.  280;141 Ref.  234;37 Ref.  
yes 25;5 0.48 [0.15;1.57] 0.22 58;30 1.01 [0.60;1.70] 0.98 30;9 0.5 [0.2;1.22] 0.13
Diabetes with 
diet3 yes 156;18 Ref.  264;131 Ref.  156;18 Ref.   
no 44;9 0.8 [0.3;2.12] 0.66 74;40 1.04 [0.65;1.67] 0.86 44;9 NA
Diabetes with oral 
medication3 yes 120;19 Ref.  278;129 Ref.  120;19 Ref.   
no 80;8 2.75 [1.04;7.26] 0.04 60;42 0.73 [0.46;1.18] 0.2 80;8 NA
Diabetes with 
insulin3 yes 123;6 Ref.  220;73 Ref.  123;6 Ref.   
no 77;21 0.2 [0.07;0.55] 0 118;98 0.52 [0.35;0.78] 0 77;21 NA
Diabetes age at 
diagnosis3 <55 32;5 Ref.  130;77 Ref.  32;5 Ref.   
55-65 56;7 2.02 [0.17;24.06] 0.58 117;50 1.81 [1.06;3.08] 0.03 56;7 NA
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>65 112;15 10.48 [0.41;270.43] 0.16 91;44 3.15 [1.74;5.69] 0 112;15 NA
Educational level <5 y 61;9 Ref.  74;40 Ref.  61;9 Ref.  
6 to 9 y 70;16 0.39 [0.11;1.4] 0.15 78;60 0.57 [0.32;1.01] 0.06 70;16 0.49 [0.19;1.28] 0.15
10 to 13 y 70;13 0.78 [0.18;3.34] 0.74 120;44 0.97 [0.51;1.84] 0.93 70;13 0.65 [0.23;1.85] 0.42
≥14 y 63;8 1.52 [0.29;7.96] 0.62 66;27 1.17 [0.59;2.30] 0.65 63;4 0.92 [0.29;2.87]  
BMI 2 years 
before2 normal 45;2 Ref.  79;49 Ref.  66;8 Ref.  
over 109;17 0.2 [0.04;0.99] 0.05 165;80 1.59 [0.97;2.62] 0.07 141;24 0.57 [0.24;1.4] 0.22
obese 46;8 0.17 [0.03;0.94] 0.04 94;42 1.62 [0.93;2.84] 0.09 57;14 0.38 [0.14;1.03] 0.06
BMI at age 20 normal 163;21 Ref.  274;147 Ref.  218;37 Ref.  
over 31;6 0.64 [0.22;1.88] 0.42 53;19 1.48 [0.81;2.69] 0.2 38;7 0.79 [0.33;1.92] 0.61
obese 6;0 NA NA 1 11;5 1.22 [0.38;3.89] 0.74 8;2 0.94 [0.10;8.55] 0.96
BMI at age 50 normal 39;9 Ref.  66;44 Ref.  60;17 Ref.  
over 100;8 3.62 [1.12;11.75] 0.03 164;77 1.29 [0.78;2.13] 0.33 129;13 2.48 [1.07;5.74] 0.03
obese 61;10 1.28 [0.43;3.79] 0.66 108;50 1.09 [0.62;1.89] 0.77 75;16 1 [0.44;2.29] 0.99
Weight gain >5kg no 26;1 Ref.  39;19 Ref.  39;7 Ref.  
yes 174;26 0.24 [0.03;1.95] 0.18 299;152 0.9 [0.48;1.68] 0.74 225;39 0.97 [0.39;2.39] 0.94
Weight gain 
>10kg no 62;10 Ref.  102;53 Ref.  90;20 Ref.  
yes 138;17 1.17 [0.47;2.89] 0.74 236;118 0.81 [0.53;1.25] 0.35 174;26 1.27 [0.65;2.47] 0.49
Weight loss since 
age 50 yes 135;21 Ref.  217;116 Ref.  175;36 Ref.  
 no 65;6 0.4 [0.13;1.21] 0.1 121;55 0.72 [0.45;1.15] 0.17 89;10 0.43 [0.2;0.96] 0.04
1Odds ratios (ORs) adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country, pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-
30, ≥30 kg/m2), except: sex in analyses stratified by sex, BMI in analyses stratified by obesity and pack-years in analyses stratified by smoking status.
2Obesity status defined based on BMI 2 years before recruitment.
3The association with PC risk could not be evaluated in reclassified NODM for diabetes-related variables due to lack of information on these variables.
. 
Page 53 of 64
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
24
Supplemental Table 10: Estimates for the observational and causal association between T2DM and PC and viceversa, applying different MRA methods, conducted among 
1,162 cases and 752 controls with epidemiological and genetic data. T2DM status based on self-reported (SR) data.
 SR-based classification of T2DM status  SR-based classification of T2DM status
 LSDM (N=289)1 NODM (N=136)1  LSDM (N=289)1 NODM (N=136)1
Diabetes-->PC OR [95%CI]2 p-value OR [95%CI]2 p-value PC-->Diabetes OR [95%CI]2 p-value OR [95%CI]2 p-value
Observational association study  Observational association study  
T2DM and PC 1.43 [1.09;1.88] 0.011 6.10 [3.45;10.8] 5.40E-13 PC and T2DM 1.45 [1.10;1.91] 0.008 6.08 [3.44;10.7] 4.80E-10
T2DM-allele score3 and T2DM in controls 1.15 [1.09;1.21] 1.20E-05 1.31 [1.15;1.47] 0.0007 PC-allele score4 and PC (without T2DM) 1.10 [1.06;1.13] 9.30E-09 1.10 [1.06;1.14] 4.10E-09
T2DM-allele score3 and PC 1.01 [0.98;1.04] 0.5 1.02 [0.98;1.05] 0.315 PC-allele score4 and T2DM 1.03 [0.99;1.06] 0.121 1.09 [1.04;1.14] 0.0002
Causal estimates: MR study  Causal estimates: MR study  
MRA_Wald 1.08 [0.86;1.29] 0.5 1.06 [0.95;1.17] 0.315 MRA_Wald 1.32 [0.97;1.67] 0.121 2.52 [2.07;3.03] 0.0002
TSLS Estimates 1.08 [0,87;1.33] 0.5 1.07 [0.96;1.20] 0.239 TSLS Estimates 1.31 [0.97;1.66] 0.123 2.52 [2.18;2.88] 0.0002
Inverse-variance weighted method (IVW) 0.90 [0.77;1.07] 0.238 0.98 [0.96;1.02] 0.692 Inverse-variance weighted method (IVW) 1.12 [0.89;1.41] 0.326 1.57 [1.13;2.12] 0.007
Mr-Egger regression 0.98 [0.74;1.30] 0.918 0.98 [0.96;1.02] 0.694 Mr-Egger regression 1.09 [0.78;1.51] 0.614 0.94 [0.57;1.55] 0.804
Mr-Egger Intercept -0.022 (0.030) 0.468 0.006 (0.018) 0.964 Mr-Egger Intercept 0.007 (0.028) 0.807 0.090 (0.042) 0.027
Weighted median 0.94 [0.73;1.22] 0.649 0.99 [0.98;1.02] 0.905 Weighted median 1.18 [0.85;1.65] 0.323 1.36 [0.85;2.16] 0.197
Simple median 0.83 [0.60;1.06] 0.117 1.03 [0.94;1.13] 0.496 Simple median 1.50 [1.00;2.26] 0.049 2.37 [1.78;2.96] <0.001
1 LSDM and NODM was evaluated in comparison to non-diabetics (1,489 subjects: 851 PC cases and 638 controls), with subjects classified as either NODM (N=136) or LSDM (N=289) being removed, respectively.
2 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, BMI (<25, 25-30, ≥30 kg/m2), smoking (never-smokers and tertiles of pack-years), country and the first five principal components for population ancestries.
3 From the 57 T2DM-SNPs, 16 were excluded due to high LD with other SNPs (r2>0.8) (Supplementary Table 1), and 6 SNPs were excluded due to their association with BMI (rs10830963, rs4430796) and smoking (rs2641348, 
rs13234407, rs1111875, rs2334499). The allele score, as instrumental variable, included the remaining 35 SNPs.
4 From the 40 PC-SNPs, 2 were excluded due to high LD (r2>0.8) (Supplementary Table 1), and 5 SNPs were excluded due to their association with BMI (rs1747924.64538961, rs2816938.199985368, rs2736098.1294086, 
rs17688601.40866663) and smoking (rs6537481.148396094). The allele score, as instrumental variable, included the remaining 33 SNPs.
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Supplemental Table 11: Estimates for the causal association between T2DM and PC and viceversa, applying different 
Multivariable MRA methods, conducted among 1,162 cases and 752 controls with epidemiological and genetic data. 
T2DM status based on self-reported (SR) data.
SR-based classification of T2DM status
 Single MRA Multivariable MRA
 
Diabetes-->PC
OR [95%CI]1
LSDM (N=289)2
OR [95%CI]1
NODM (N=136)2
OR [95%CI]1
LSDM2 (X1) + BMI (X2) -> PC
OR [95%CI]1
NODM2 (X1) + BMI (X2) -> PC
TSLS Estimates 1.08 [0,87;1.33] 1.07 [0.96;1.20] 1.08 [0.84;1.41] 1.06 [0.95;1.19]
Inverse-variance weighted method (IVW) 0.90 [0.77;1.07] 0.98 [0.96;1.02] 0.94 [0.80;1.10] 1.00 [0.99;1.01]
Mr-Egger regression 0.98 [0.74;1.30] 0.98 [0.96;1.02] 1.00 [0.76;1.30] 1.00 [0.99;1.01]
Mr-Egger Intercept ´-0.022; p=0.468 0.006; p=0.964 ´-0.014; p=0.54 0.001; p=0.93
PC-->Diabetes   PC (X1) + BMI (X2) -> NODM PC (X1) + BMI (X2) -> LSDM
TSLS Estimates 1.03 [0.99;1.06] 2.52 [2.05;3.03] 1.05 [0.90;1.20] 1.31 [1.10;1.52]
Inverse-variance weighted method (IVW) 1.12 [0.89;1.41] 1.57 [1.13;2.12] 1.20 [0.98;1.48] 1.58 [1.15;2.17]
Mr-Egger regression 1.09 [0.78;1.51] 0.94 [0.57;1.55] 1.21 [0.87;1.69] 1.19 [0.72;1.96]
Mr-Egger Intercept 0.007; p=0.81 0.090; p=0.027 ´-0.002; p=0.93 0.063; p=0.14
PC-->Diabetes (without outliers)3   PC (X1) + BMI (X2) -> NODM PC (X1) + BMI (X2) -> LSDM
TSLS Estimates 1.38 [0.95;1.99] 2.85 [2.04;3.98]
Inverse-variance weighted method (IVW) 1.18 [0.93;1.51] 1.52 [1.08;2.13] 1.19 [0.97;1.42] 1.77 [1.46;2.08]
Mr-Egger regression 1.18 [0.84;1.66] 1.36 [0.80;2.32] 1.28 [0.87;1.87] 1.65 [0.98;2.77]
Mr-Egger Intercept 0.001; p=0.96 0.023; p=0.6 ´-0.01; p=0.645 0.01; p=0.73
From the 57 T2DM-SNPs, 16 were excluded due to high LD with other SNPs (r2>0.8) (Supplementary Table 1), and 4 SNPs was excluded due to its association 
with smoking (rs2641348, rs13234407, rs1111875, rs2334499). The allele score, as instrumental variable, included the remaining 37 SNPs. SNPs associated 
with obesity were not excluded.
From the 40 PC-SNPs, 2 were excluded due to high LD (r2>0.8) (Supplementary Table 1), and 1 SNPs was excluded due to its association with smoking 
(rs6537481.148396094). The allele score, as instrumental variable, included the remaining 37 SNPs. SNPs associated with obesity were not excluded.
1 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, BMI (<25, 25-30, ≥30 kg/m2), smoking (never-smokers and tertiles of pack-years), 
country and the first five principal components for population ancestries.
2 LSDM and NODM was evaluated in comparison to non-diabetics (1,489 subjects: 851 PC cases and 638 controls), with subjects classified as either NODM 
(N=136) or LSDM (N=289) being removed, respectively. BMI to define obesity (yes, no) two years before recruitment.
3 Outliers removed: "rs1747924:64538961:C:A", "rs1486134:67639769:G:T", "rs17688601:40866663:C:A" for LDSM and "rs6971499" and "rs7310409” for NODM
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Supplemental Table 12: Estimates for the observational and causal association between obesity measures and PC, 
applying different MRA methods, conducted among 1,162 cases and 752 controls with epidemiological and genetic 
data.
 SR-based classification of obesity status
 BMI  2 years (N=343 obese) BMI  50 years (N=401 obese)
BMI-->PC OR [95%CI]1 p-value OR [95%CI]1 p-value
Observational association study  
BMI and PC 0.89 [0.69;1.14] 0.356 0.83 [0.64;1.07] 1.41E-01
BMI-allele score2 and BMI in controls 1.11 [1.08;1.15] 3.06E-09 1.16 [1.12;1.21] 1.71E-11
BMI-allele score2 and PC 1.01 [0.98;1.02] 0.927 1.01 [0.99;1.03] 0.311
Causal estimates: MR study  
MRA_Wald 1.01 [0.98;1.03] 0.927 1.07 [0.94;1.21] 0.311
TSLS Estimates 1.01 [0,85;1.20] 0.927 1.09 [0.95;1.25] 0.293
Inverse-variance weighted method 
(IVW) 1.01 [0.90;1.15] 0.828 1.03 [0.93;1.14] 0.542
Mr-Egger regression 0.98 [0.74;1.30] 0.794 0.97 [0.82;1.15] 0.705
Mr-Egger Intercept 0.009(0.015) 0.573 0.016 (0.017) 0.343
Weighted median 0.96 [0.80;1.32] 0.688 1.03 [0.88;1.20] 0.728
Simple median 1.10 [0.92;1.32] 0.278 1.05 [0.90;1.22] 0.554
1 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, smoking (never-smokers and tertiles of pack-years), country and the first five principal 
components for population ancestries.
4 From the 126 obesity-SNPs, 30 were excluded due to high LD (r2>0.8) (Supplementary Table 1), and 11 SNPs were excluded due to their association with 
T2DM and smoking. The allele score, as instrumental variable, included the remaining 85 SNPs.
There were few obese subjects at age 20 years; BMI at this age was therefore not considered.
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Supplemental Table 13: Results of causal mediation analyses evaluating mediator effects of T2DM on the obesity and 
PC association considering different obesity measures, and mediator effects of obesity on the T2DM and PC association. 
Estimates are derived from counterfactual models (2,018 cases and 1,540 controls) and MRA (1,162 cases and 752 
controls with epidemiological and genetic data). 
OR1 [95%CI] OR1 [95%CI] OR1 [95%CI] OR1 [095%CI] OR1 [95%CI] OR1 [95%CI]
Counterfactual model NDE  NIE  TE  NDE  NIE  TE  
NODM mediator       LSDM mediator
Obese2 0.90 [0.73;1.10] 1.04 [1.01;1,11] 0.94 [0.77;1.17] 0.95 [0.80;1.15] 1.05 [1.02;1.10] 1.00 [0.84;1.22]
Overweight/obese2 0.83 [0.71;0.98] 1.09 [1.08;1,13] 0.91 [0.79;1.11] 0.92 [0.80;1.08] 1.03 [1.01;1.06] 0.95 [0.82;1.11]
Weight gain > 5 kg3 0.82 [0.66;0.97] 1.08 [1.07;1.10] 0.89 [0.72;1.07] 0.86 [0.70;1.03] 1.05 [1.03;1.08] 0.89 [0.74;1.08]
Weight loss3 1.04 [0.85;1.38] 0.95 [0.73;1.02] 1.00 [0.83;1.19] 0.98 [0.82;1.15] 1.02 [1.00;1.04] 1.00 [0.84;1.17]
Obese at age 503 0.83 [0.67;1.01] 1.07 [1.04;1,13] 0.89 [0.73;1.08] 0.88 [0.72;1.07] 1.07 [1.04;1.15] 0.94 [0.78;1.14]
Overweight/obese at age 503 1.21 [1.01;1.44] 1.03 [0.98;1.08] 1.25 [1.07;1.51] 1.18 [1.01;1.37] 1.04 [1.03;1.07] 1.23 [1.06;1.43]
Obese2 mediator Overweight/obese2 mediator
NODM 5.92 [3.69;9.14] 0.97 [0.78;1.01] 5.72 [3.76;9.11] 10.14 [5.48;22.69] 0.55 [0.23;0.92] 5.58 [3.65;8.92]
LSDM 1.65 [1.34;2.03] 1.02 [0.99;1.07] 1.68 [1.37;2.06] 1.61 [1.31;2.00] 1.03 [1.01;1.08] 1.67 [1.35;2.06]
Obese at age 503 mediator Overweight/obese at age 503 mediator
NODM 4.99 [2.54;10.87] 0.87 [0.43;1.04] 4.35 [2.35;9.65] 4.27 [2.14;8.08] 1.08 [1.03;1.12] 4.63 [2.66;10.82]
LSDM 1.53 [1.13;2.09] 0.99 [0.87;1.07] 1.50 [1.14;2.17] 1.38 [1.08;1.94] 1.09 [1.03;1.15] 1.49 [1.17;2.02]
Counterfactual IV NDE  NIE  TE  NDE  NIE  TE  
NODM mediator LSDM mediator
Obese2 0.83 [0.63;1.15] 1.03 [1.00;1.11] 0.85 [0.68;1.24] 0.88 [0.63;1.27] 1.02 [0.99;1.04] 0.89 [0.68;1.27]
Overweight/obese2 0.93 [0.72;1.12] 1.05 [1.00;1.08] 0.97 [0.81;1.26] 0.98 [0.81;1.27] 1.01 [0.99;1.02] 0.98 [0.79;1.27]
Weight gain > 5 kg3 1.15 [0.68;1.53] 1.03 [1.00;1.07] 1.19 [0.68;1.56] 1.16 [0.94;1.58] 1.02 [1.00;1.03] 1.18 [0.95;1.78]
Weight loss3 1.20 [0.96;1.69] 0.94 [0.90;0.98] 1.13 [0.92;1.48] 1.13 [0.88;1.35] 1.01 [0.99;1.02] 1.14 [0.88;1.39]
Obese at age 503 0.82 [0.66;1.22] 1.06 [1.00;1.12] 0.87 [0.70;1.31] 0.84 [0.66;1.12] 1.02 [1.00;1.06] 0.86 [0.68;1.13]
Overweight/obese at age 503 1.44 [1.18;1.89] 1.03 [1.00;1.06] 1.49 [1.23;1.96] 1.47 [1.17;1.88] 1.02 [1.01;1.03] 1.49 [1.19;1.90]
Obese2 mediator Overweight/obese2 mediator
NODM 5.06 [3.15;13.19] 0.92 [0.40;1.01] 4.67 [2.97;9.77] 8.21 [6.64;11.58] 0.53 [0.38;0.75] 4.37 [3.02;7.75]
LSDM 1.46 [1.02;1.91] 1.02 [0.97;1.07] 1.47 [1.07;2.01] 1.45 [1.12;2.18] 1.01 [0.94;1.04] 1.46 [1.22;2.29]
Obese at age 503 mediator Overweight/obese at age 503 mediator
NODM 5.01 [3.02;12.20] 0.86 [0.37;1.06] 4.32 [2.78;8.77] 4.28 [2.72;9.79] 1.09 [1.05;1.20] 4.68 [3.04;11.49]
LSDM 1.51 [1.24;2.20] 0.98 [0.87;1.04] 1.49 [1.25;2.32] 1.37 [0.88;1.81] 1.08 [1.03;1.16] 1.48 [1.07;2.15]
CI, confidence interval; TE, marginal total effect; NDE, natural direct effect; NIE, natural indirect effect; 
1 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, smoking (never-smokers and tertiles of pack-years), country, and the first five 
principal components for population ancestries in network MRA
2 Obesity status defined based on BMI 2 years before recruitment 
3 Obesity-related variables based on information collected at age 50 years, such as weight gain from age 20 to 50 and weight loss since age 50 years
Significant estimates are marked in bold.
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Supplemental Table 14: Association between diabetes-related variables and PC risk in the PanGenEU study (2,018 
cases and 1,540 controls). Unimputed data.
  Cases Controls      
N=2,018 N=1,540  Model1              Model2
  N % N % p-value1 OR [95%CI] OR [95%CI]
Diabetes status <0.001
    no diabetes 1479 73.30 1340 87.00 Ref. Ref.
    yes 498 24.70 184 11.90 2.60 [2.13;3.18] 2.55 [2.04;3.18]
   Missing 41 2.03 16 1.04
Diabetes status by subtype <0.001
no diabetes 1479 73.30 1340 87.00 Ref. Ref.
yes, ≤ 2 years (NODM) 200 9.91 27 1.75 6.41 [4.2;9.79] 6.43 [4.06;10.2]
yes, > 2years (LSDM) 265 13.10 152 9.87 1.82 [1.45;2.3] 1.77 [1.37;2.28]
Missing 74 3.67 21 1.36
Family history of diabetes2
no diabetes 1069 58.0 821 65.7 Ref. Ref.
yes 594 32.2 357 28.6 1.24 [1.04;1.49] 1.14 [1.00;1.38]
Missing 182 9.9 72 5.8
Diabetes by age at diagnosis3 <0.001
no diabetes 1479 73.30 1340 87.00 Ref. Ref.
≤ 55 years 141 6.99 72 4.68 1.66 [1.21;2.28] 1.59 [1.12;2.26]
55 to ≤ 65 years 138 6.84 50 3.25 2.48 [1.74;3.55] 2.48 [1.69;3.64]
> 65 years 197 9.76 58 3.77 3.97 [2.88;5.54] 3.79 [2.67;5.44]
Missing 63 3.12 20 1.30 p-trend 2E-16 2E-16
Diabetes by time since diagnosis3 <0.001
   no diabetes 1479 73.30 1340 87.0 Ref. Ref.
   ≤1 159 7.88 12 0.78 10.98 [6;20.09] 9.39 [5.08;17.34]
   1 to ≤2 41 2.03 15 0.97 2.64 [1.4;4.97] 3.19 [1.56;6.52]
   2 to ≤5 71 3.52 32 2.08 2.38 [1.54;3.75] 2.43 [1.52;3.94]
   5 to ≤10 86 4.26 36 2.34 2.43 [1.60;3.73] 2.41 [1.52;3.86]
   10 to ≤20 56 2.78 40 2.60 1.50 [0.96;2.33] 1.38 [0.85;2.25]
   >20 52 2.58 44 2.86 1.21 [0.78;1.90] 1.11 [0.67;1.81]
  Missing 74 3.67 21 1.36 p-trend 1.5E-06 4.5E-05
Diabetes control measures
Diet <0.001
no diabetes 1479 73.30 1340 87.00 Ref. Ref.
yes 297 14.70 133 8.64 2.50 [1.98;3.15] 2.44 [1.9;3.14]
no use 118 5.85 49 3.18 2.41 [1.68;3.46] 2.38 [1.6;3.55] 
Missing 124 6.14 18 1.17
Use of oral medication <0.001
no diabetes 1479 73.30 1340 87.00 Ref. Ref.
yes 304 15.10 130 8.44 2.36 [1.86;2.99] 2.24 [1.73;2.9]
no use 140 6.94 50 3.25 3.00 [2.12;4.24] 3.21 [2.17;4.74]
Missing 95 4.71 20 1.30
Use of insulin <0.001
no diabetes 1479 73.30 1340 87.00 Ref. Ref.
yes 236 11.70 59 3.83 4.26 [3.12;5.81] 4.18 [2.97;5.89]
no use 195 9.66 119 7.73 1.77 [1.37;2.28] 1.77 [1.34;2.35]
Missing 108 5.35 22 1.43
1 Differences between groups evaluated by the Chi-square test
2 Information on family history of diabetes was not collected in Ireland; results are based on data for 1,845 cases and 1,250 controls
3 Linear association for age since T2DM diagnosis and nonlinear association for time since T2DM (Supplemental Figure 1)
Model 1: adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, country.
Model 2: Model 1 also adjusted for pack years (never-smokers and tertiles of pack-years) and BMI (<25, 25-30, ≥30 kg/m2)
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Supplemental Table 15: Estimates for the observational and causal association between T2DM and PC and vice versa, applying different MRA methods, conducted among 
1,162 cases and 752 controls with epidemiological and genetic data. T2DM status based on self-reported (SR) and biomarker data.
 SR + biomarker-based classification of T2DM status  SR + biomarker -based classification of T2DM status
 LSDM (N=289)1 NODM (N=190)1  LSDM (N=289)1 NODM (N=190)1
Diabetes-->PC OR [95%CI]2 p-value OR [95%CI]2 p-value PC-->Diabetes OR [95%CI]2 p-value OR [95%CI]2 p-value
Observational association study  Observational association study  
T2DM and PC 1.50 [1.14;1.98] 0.003 5.08 [3.27;7.90] 4.40E-13 PC and T2DM 1.51 [1.15;2.00] 0.003 5.15 [3.31;8.00] 3.22E-13
T2DM-allele score3 and T2DM in controls 1.11 [1.05;1.16] 3.73E-04 1.23 [1.13;1.33] 4.74E-05 PC-allele score4 and PC (without T2DM) 1.10 [0.75;1.45] 1.54E-08 1.09 [1.07;1.13] 1.54E-08
T2DM-allele score3 and PC 1.02 [0.99;1.05] 0.146 0.99 [0.96;1.02] 0.461 PC-allele score4 and T2DM 1.03 [0.99;1.06] 0.119 1.07 [1.03;1.11] 0.0014
Causal estimates: MR study  Causal estimates: MR study  
MRA_Wald 1.21 [0.95;1.47] 0.146 0.95 [0.96;1.02] 0.461 MRA_Wald 1.32 [0.97;1.67] 0.12 2.01 [1.58;2.43] 0.0014
T2LS Estimates 1.19 [0.92;1.54] 0.194 0.95 [0.84;1.08] 0.461 T2LS Estimates 1.03 [0.99;1.06] 0.12 2.86 [2.07;3.97] 2.37E-10
Inverse-variance weighted method (IVW) 1.06 [0.79;1.42] 0.708 0.99 [0.93;1.05] 0.725 Inverse-variance weighted method (IVW) 1.12 [0.89;1.41] 0.316 1.29 [0.98;1.70] 0.078
Mr-Egger regression 1.31 [0.80;2.15] 0.278 1.00 [0.94;1.06] 0.921 Mr-Egger regression 1.05 [0.76;1.47] 0.756 0.83 [0.55;1.26] 0.382
Mr-Egger Intercept ´-0.049 (0.045) 0.283 ´-0.019 (0.029) 0.538 Mr-Egger Intercept 0.015 (0.028) 0.604 0.095 (0.034) 0.005
Weighted median 0.97 [0.72;1.30] 0.823 1.00 [0.96;1.04] 0.812 Weighted median 1.22 [0.88;1.17* 0.238 1.16 [0.78;1.75] 0.446
Simple median 1.20 [0.86;1.70] 0.284 1.00 [0.85;1.17] 0.95 Simple median 1.55 [1.00;2.32] 0.05 1.56 [0.96;2.54] 0.075
1 LSDM and NODM was evaluated in comparison to non-diabetics after reclassifying T2DM status with the biomarker data (obtained for 654 subjects with epidemiological and genetic data), with subjects reclassified as either NODM 
(N=190) or LSDM (N=289) being removed, respectively.
2 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, BMI (<25, 25-30, ≥30 kg/m2), smoking (never-smokers and tertiles of pack-years), country and the first five principal components for population ancestries.
3 From the 57 T2DM-SNPs, 16 were excluded due to high LD with other SNPs (r2>0.8) (Supplementary Table 1), and 6 SNPs were excluded due to their association with BMI (rs10830963, rs4430796) and smoking (rs2641348, 
rs13234407, rs1111875, rs2334499). The allele score, as instrumental variable, included the remaining 35 SNPs.
4 From the 40 PC-SNPs, 2 were excluded due to high LD (r2>0.8), and 5 SNPs were excluded due to their association with BMI (rs1747924.64538961, rs2816938.199985368, rs2736098.1294086, rs17688601.40866663) and smoking 
(rs6537481.148396094). The allele score, as instrumental variable, included the remaining 33 SNPs.
Removal of SNPs  potentially associated with other traits (at p-value 10-8) according to PhenoScanner database led to similar results.
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Supplemental Table 16: Estimates for the observational and causal association between T2DM and PC and vice versa, after removing other potential pleiotropic variants and 
outliers (based on Cook´s distances) and applying different MRA methods, conducted among 1,162 cases and 752 controls with epidemiological and genetic data. T2DM status 
based on self-reported (SR) data.
 SR-based classification of T2DM status  SR-based classification of T2DM status
 LSDM (N=289)1 NODM (N=136)1  LSDM (N=289)1 NODM (N=136)1
Diabetes-->PC OR [95%CI]2 p-value OR [95%CI]2 p-value PC-->Diabetes OR [95%CI]2 p-value OR [95%CI]2 p-value
Observational association study  Observational association study  
T2DM and PC 1.43 [1.09;1.88] 0.011 6.10 [3.45;10.8] <0.001 PC and T2DM 1.45 [1.10;1.91] 0.008 6.08 [3.44;10.7] 4.80E-10
T2DM-allele score3 and T2DM in controls 1.16 [1.09;1.22] 1.42E-05 1.32 [1.15;1.48] 0.001 PC-allele score4 and PC (without T2DM) 1.10 [1.06;1.13] 4.10E-08 1.10 [1.06;1.13] 3.10E-08
T2DM-allele score3 and PC 1.00 [0.97;1.03] 9.93E-01 1.01 [0.98;1.05] 0.389 PC-allele score4 and T2DM 1.03 [1.00;1.06] 0.09 1.08 [1.03;1.13] 0.0023
Causal estimates: MR study  Causal estimates: MR study  
MRA_Wald 1.00 [0.79;1.22] 0.273 1.05 [0.99;1.09] 0.389 MRA_Wald 1.38 [0.99;1.74] 0.09 2.47 [1.71;2.74] 0.00053
TSLS Estimates 0.98 [0.79;1.22] 0.864 1.05 [0.93;1.19] 0.39 TSLS Estimates 1.38 [0.95;1.99] 0.09 2.85 [2.04;3.98] 2.80E-09
Inverse-variance weighted method (IVW) 0.92 [0.79;1.08] 0.315 1.00 [0.96;1.02] 0.538 Inverse-variance weighted method (IVW) 1.18 [0.93;1.51] 0.16 1.52 [1.08;2.13] 0.016
Mr-Egger regression 1.00 [0.77;1.20] 0.992 0.98 [0.96;1.02] 0.534 Mr-Egger regression 1.18 [0.84;1.66] 0.348 1.36 [0.80;2.32] 0.251
Mr-Egger Intercept 0.019 (0.025) 0.448 0.001 (0.018) 0.936 Mr-Egger Intercept 0.001 (0.028) 0.963 0.023 (0.043) 0.06
Weighted median 0.96 [0.74;1.24] 0.481 1.01 [0.95;1.04] 0.966 Weighted median 1.18 [0.84;1.67] 0.321 1.43 [0.88;2.33] 0.15
Simple median 0.86 [0.69;1.07] 0.174 1.02 [0.92;1.11] 0.735 Simple median 1.51 [1.00;2.27] 0.052 2.84 [2.27;3.41] <0.001
1 LSDM and NODM was evaluated in comparison to non-diabetics (1,489 subjects: 851 PC cases and 638 controls), with subjects classified as either NODM (N=136) or LSDM (N=289) being removed, respectively.
2 All estimates were adjusted for age (<55, 55-65, 65-75, ≥75 years), gender, BMI (<25, 25-30, ≥30 kg/m2), smoking (never-smokers and tertiles of pack-years), country and the first five principal components for population ancestries.
3 From the 57 T2DM-SNPs, 16 were excluded due to high LD with other SNPs (r2>0.8) (Supplementary Table 1), and 6 SNPs were excluded due to their association with BMI (rs10830963, rs4430796) and smoking (rs2641348, 
rs13234407, rs1111875, rs2334499). In addition, 3 SNPs potentially being outliers were removed (rs2191348, rs13266634, rs7965349). The allele score, as instrumental variable, included the remaining 32 SNPs.
4 From the 40 PC-SNPs, 2 were excluded due to high LD (r2>0.8) (Supplementary Table 1), and 5 SNPs were excluded due to their association with BMI (rs1747924.64538961, rs2816938.199985368, rs2736098.1294086, 
rs17688601.40866663) and smoking (rs6537481.148396094). In addition, 2 SNPs potentially being outliers were removed (chr12_121454622, chr16_75263661). The allele score, as instrumental variable, included the remaining 31 SNPs.
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Supplemental Table 17: Magnitudes of the E-value for different combinations of the Exposure-Confounder Association 
RREU and the Confounder-Outcome Association RRUD for the estimation of the causal effect of NODM on PC (OR=6.39 
(4.18;9.78)) and of LSDM on PC (OR=1.86 (1.49;2.32)). 
NODM
RRUDE-value
3.5 6.5 9.5 12.5 15.5 18.5 21.5 24.5 27.5
3.5 2,04 2,53 2,77 2,92 3,01 3,08 3,14 3,18 3,21
6.5 2,53 3,52 4,12 4,51 4,80 5,01 5,18 5,31 5,42
9.5 2,77 4,12 5,01 5,65 6,14 6,51 6,81 7,05 7,26
12.5 2,92 4,51 5,65 6,51 7,18 7,71 8,14 8,51 8,81
15.5 3,01 4,80 6,14 7,18 8,01 8,69 9,26 9,74 10,15
18.5 3,08 5,01 6,51 7,71 8,69 9,51 10,20 10,79 11,31
21.5 3,14 5,18 6,81 8,14 9,26 10,20 11,01 11,71 12,32
24.5 3,18 5,31 7,05 8,51 9,74 10,79 11,71 12,51 13,21
RREU
27.5 3,21 5,42 7,26 8,81 10,15 11,31 12,32 13,21 14,00
   LSDM
RRUDE-value
1.5 2.5 3.5 4.5 5.5 6.5 7.5 8.5 9.5 10.5
1.5 1,13 1,25 1,31 1,35 1,38 1,39 1,41 1,42 1,43 1,43
2.5 1,25 1,56 1,75 1,88 1,96 2,03 2,08 2,13 2,16 2,19
3.5 1,31 1,75 2,04 2,25 2,41 2,53 2,63 2,70 2,77 2,83
4.5 1,35 1,88 2,25 2,53 2,75 2,93 3,07 3,19 3,29 3,38
5.5 1,38 1,96 2,41 2,75 3,03 3,25 3,44 3,60 3,73 3,85
6.5 1,39 2,03 2,53 2,93 3,25 3,52 3,75 3,95 4,12 4,27
7.5 1,41 2,08 2,63 3,07 3,44 3,75 4,02 4,25 4,45 4,63
8.5 1,42 2,13 2,70 3,19 3,60 3,95 4,25 4,52 4,75 4,96
9.5 1,43 2,16 2,77 3,29 3,73 4,12 4,45 4,75 5,01 5,25
RREU
10.5 1,43 2,19 2,83 3,38 3,85 4,27 4,63 4,96 5,25 5,51
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Supplemental Figure 1: Directed acyclic graphs illustrating the single MR and multivariable and network MR 
approaches used to explore causal associations and mediation in the causal pathways between T2DM, obesity and PC.
A: Observational association between T2DM (Exposure) and PC (Outcome)
B: Single Mendelian Randomization (MR) between T2DM (Exposure) and PC (Outcome)
C: Single Mendelian Randomization (MR) between PC (Exposure) and T2DM (Outcome) – bidirectional MR
D: Multivariable Mendelian Randomization (MR) between T2DM (Exposure) and PC (Outcome)
E: Multivariable Mendelian Randomization (MR) between PC (Exposure) and T2DM (Outcome) – bidirectional MR
F: Network Mendelian Randomization (MR) between T2DM (Exposure), Obesity (Mediator) and PC (Outcome)
G: Network Mendelian Randomization (MR) between Obesity (Exposure), T2DM (Mediator) and PC (Outcome)
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Supplemental Figure 2: Linear and Non-linear association between T2DM-related continuous variables and pancreatic cancer risk, with non-diabetics as a reference group: (A) 
time since T2DM diagnosis; (B) age at T2DM diagnosis; (C) Hb1Ac levels and (D) C-Peptide levels with the minimum value (Hb1Ac=4; C-Peptide=0.05) as the reference group. 
A                                                                                                                                                 B
C D
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Supplemental Figure 3: Pleiotropy visualization plots regarding the directional association between PC and NODM risk. 
A: funnel plot for IV made up of SNPs without SNPs in LD and SNPs associated with obesity and smoking. B: funnel plot for IV excluding further SNPs that were outliers (based 
on Cooks distances). Y-axes represent SNP to outcome effect corrected by SNP to exposure standard error of the effect. X-axes (SNP to exposure effect) are in logarithmic 
scale. C: Correlation plot of per-allele associations (genetic score of the IV) with the outcome and exposure. D: Forest plot of per-allele MR effect size for exposure on outcome 
and E: leave-one-out analyses. 
A                                                                                          B C
D E
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